WO2003078424A1 - Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone - Google Patents
Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone Download PDFInfo
- Publication number
- WO2003078424A1 WO2003078424A1 PCT/US2003/007938 US0307938W WO03078424A1 WO 2003078424 A1 WO2003078424 A1 WO 2003078424A1 US 0307938 W US0307938 W US 0307938W WO 03078424 A1 WO03078424 A1 WO 03078424A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- anthracene
- boronobenzyl
- benzyl
- compound
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 173
- 239000008103 glucose Substances 0.000 title claims abstract description 168
- 229940061720 alpha hydroxy acid Drugs 0.000 title claims abstract description 14
- 150000001280 alpha hydroxy acids Chemical class 0.000 title claims abstract description 14
- 238000001514 detection method Methods 0.000 title claims description 46
- 150000001875 compounds Chemical class 0.000 claims abstract description 109
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 37
- 230000003993 interaction Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 23
- SERHXTVXHNVDKA-UHFFFAOYSA-N pantolactone Chemical compound CC1(C)COC(=O)C1O SERHXTVXHNVDKA-UHFFFAOYSA-N 0.000 claims abstract description 5
- -1 boronate ion Chemical group 0.000 claims description 263
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 151
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 118
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 89
- 239000007787 solid Substances 0.000 claims description 74
- 239000011159 matrix material Substances 0.000 claims description 72
- 125000006308 propyl amino group Chemical group 0.000 claims description 51
- 125000005647 linker group Chemical group 0.000 claims description 39
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000005620 boronic acid group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 230000003301 hydrolyzing effect Effects 0.000 claims description 11
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 8
- 150000002009 diols Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical group C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 230000000704 physical effect Effects 0.000 claims description 6
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical group O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 229940006020 arsenite ion Drugs 0.000 claims description 5
- OWTFKEBRIAXSMO-UHFFFAOYSA-N arsenite(3-) Chemical group [O-][As]([O-])[O-] OWTFKEBRIAXSMO-UHFFFAOYSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- YBMRDBCBODYGJE-UHFFFAOYSA-N germanium dioxide Chemical group O=[Ge]=O YBMRDBCBODYGJE-UHFFFAOYSA-N 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- FXADMRZICBQPQY-UHFFFAOYSA-N orthotelluric acid Chemical group O[Te](O)(O)(O)(O)O FXADMRZICBQPQY-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000010791 quenching Methods 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- 210000001742 aqueous humor Anatomy 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 210000003722 extracellular fluid Anatomy 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000004243 sweat Anatomy 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 7
- 125000005577 anthracene group Chemical group 0.000 claims 6
- 150000007933 aliphatic carboxylic acids Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 34
- 229910052796 boron Inorganic materials 0.000 description 116
- 239000000243 solution Substances 0.000 description 101
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 92
- 238000004128 high performance liquid chromatography Methods 0.000 description 61
- UFFSXJKVKBQEHC-UHFFFAOYSA-N heptafluorobutyric anhydride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)C(F)(F)F UFFSXJKVKBQEHC-UHFFFAOYSA-N 0.000 description 58
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 56
- 239000002953 phosphate buffered saline Substances 0.000 description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 51
- 229940001447 lactate Drugs 0.000 description 51
- 239000000178 monomer Substances 0.000 description 47
- 238000002347 injection Methods 0.000 description 46
- 239000007924 injection Substances 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 239000000017 hydrogel Substances 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 28
- 230000014759 maintenance of location Effects 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- 239000003643 water by type Substances 0.000 description 21
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 20
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 16
- 239000004926 polymethyl methacrylate Substances 0.000 description 16
- 230000005284 excitation Effects 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 239000010408 film Substances 0.000 description 13
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 239000008363 phosphate buffer Substances 0.000 description 11
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 10
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 9
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical class [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- UBSMRVSDSPJXBM-UHFFFAOYSA-N [2-(bromomethyl)phenyl]-(2,2-dimethylpropoxy)borinic acid Chemical compound CC(C)(C)COB(O)C1=CC=CC=C1CBr UBSMRVSDSPJXBM-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- UOSROERWQJTVNU-UHFFFAOYSA-N 9,10-bis(chloromethyl)anthracene Chemical compound C1=CC=C2C(CCl)=C(C=CC=C3)C3=C(CCl)C2=C1 UOSROERWQJTVNU-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 229930091371 Fructose Natural products 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 230000002452 interceptive effect Effects 0.000 description 7
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 6
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- ODGVQFZYEVKOMA-UHFFFAOYSA-N OBO.OBO.C1=CC=CC2=CC3=CC=CC=C3C=C21 Chemical compound OBO.OBO.C1=CC=CC2=CC3=CC=CC=C3C=C21 ODGVQFZYEVKOMA-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 5
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- XHIRWEVPYCTARV-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide;hydrochloride Chemical compound Cl.CC(=C)C(=O)NCCCN XHIRWEVPYCTARV-UHFFFAOYSA-N 0.000 description 5
- XVEFYBPVIQRYGK-UHFFFAOYSA-N n-[3-[(3,4-dihydroxy-9,10-dioxoanthracen-2-yl)sulfonylamino]propyl]-2-methylprop-2-enamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S(=O)(=O)NCCCNC(=O)C(=C)C)C(O)=C2O XVEFYBPVIQRYGK-UHFFFAOYSA-N 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- UZNHKBFIBYXPDV-UHFFFAOYSA-N trimethyl-[3-(2-methylprop-2-enoylamino)propyl]azanium;chloride Chemical compound [Cl-].CC(=C)C(=O)NCCC[N+](C)(C)C UZNHKBFIBYXPDV-UHFFFAOYSA-N 0.000 description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000001540 sodium lactate Substances 0.000 description 3
- 229940005581 sodium lactate Drugs 0.000 description 3
- 235000011088 sodium lactate Nutrition 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 2
- ROIXSNLOYHDYBP-UHFFFAOYSA-N 2-[2-(bromomethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC=C1CBr ROIXSNLOYHDYBP-UHFFFAOYSA-N 0.000 description 2
- REESGCUCRJOWQY-UHFFFAOYSA-N 2-[2-[[10-(chloromethyl)anthracen-9-yl]methylamino]ethoxy]ethanol;hydrochloride Chemical compound Cl.C1=CC=C2C(CNCCOCCO)=C(C=CC=C3)C3=C(CCl)C2=C1 REESGCUCRJOWQY-UHFFFAOYSA-N 0.000 description 2
- BZDXPPOWPSGAFW-UHFFFAOYSA-N 2-[2-[[10-[[2-(2-hydroxyethoxy)ethylamino]methyl]anthracen-9-yl]methylamino]ethoxy]ethanol Chemical compound C1=CC=C2C(CNCCOCCO)=C(C=CC=C3)C3=C(CNCCOCCO)C2=C1 BZDXPPOWPSGAFW-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- NUNZKXMLKLSPMQ-UHFFFAOYSA-N 2-methyl-n-[3-[[4-methyl-10-[3-(2-methylprop-2-enoylamino)propylamino]anthracen-9-yl]amino]propyl]prop-2-enamide Chemical compound C1=CC=C2C(NCCCNC(=O)C(=C)C)=C(C=CC=C3)C3=C(NCCCNC(=O)C(C)=C)C2=C1C NUNZKXMLKLSPMQ-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- NIXVAPHNPNMUIX-UHFFFAOYSA-N 6-amino-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCN NIXVAPHNPNMUIX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- VCNRFMYXRDBOFT-UHFFFAOYSA-N FC(C(=O)O)(F)F.C12=CC=CC3=CC=CC(=C13)C(NC2=O)=O Chemical compound FC(C(=O)O)(F)F.C12=CC=CC3=CC=CC(=C13)C(NC2=O)=O VCNRFMYXRDBOFT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- DYBXVITUBPGBBW-UHFFFAOYSA-N anthracen-1-ylboronic acid Chemical compound C1=CC=C2C=C3C(B(O)O)=CC=CC3=CC2=C1 DYBXVITUBPGBBW-UHFFFAOYSA-N 0.000 description 2
- REJFOBQJXSGDSB-UHFFFAOYSA-N anthracene-9-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=C(C=CC=C3)C3=CC2=C1 REJFOBQJXSGDSB-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000003269 fluorescent indicator Substances 0.000 description 2
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- SQJPLKCVYHDHJE-UHFFFAOYSA-N n'-[[4-(dimethylamino)phenyl]methyl]hexane-1,6-diamine Chemical compound CN(C)C1=CC=C(CNCCCCCCN)C=C1 SQJPLKCVYHDHJE-UHFFFAOYSA-N 0.000 description 2
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- NOKCAOZCPJRWQB-UHFFFAOYSA-N n-(6-aminohexyl)anthracene-9-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C(=O)NCCCCCCN)=C(C=CC=C3)C3=CC2=C1 NOKCAOZCPJRWQB-UHFFFAOYSA-N 0.000 description 2
- SIMOTMKBMCLWSE-UHFFFAOYSA-N n-(6-aminohexyl)cyclohexanecarboxamide Chemical compound NCCCCCCNC(=O)C1CCCCC1 SIMOTMKBMCLWSE-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- MRQAWLGOMWJSPJ-UHFFFAOYSA-N n-[3-(2,5-dimethylanilino)propyl]-2-methylprop-2-enamide Chemical group CC(=C)C(=O)NCCCNC1=CC(C)=CC=C1C MRQAWLGOMWJSPJ-UHFFFAOYSA-N 0.000 description 2
- KFDMMDYFHXLBNV-UHFFFAOYSA-N n-[3-[[10-[[2-(2-hydroxyethoxy)ethylamino]methyl]anthracen-9-yl]methylamino]propyl]-2-methylprop-2-enamide Chemical compound C1=CC=C2C(CNCCCNC(=O)C(=C)C)=C(C=CC=C3)C3=C(CNCCOCCO)C2=C1 KFDMMDYFHXLBNV-UHFFFAOYSA-N 0.000 description 2
- BYVCTYDTPSKPRM-UHFFFAOYSA-N naphthalene-1-carbonyl naphthalene-1-carboxylate Chemical compound C1=CC=C2C(C(OC(=O)C=3C4=CC=CC=C4C=CC=3)=O)=CC=CC2=C1 BYVCTYDTPSKPRM-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- OVGSAMHLIFJBCO-UHFFFAOYSA-N tert-butyl 3-[[10-[[[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]amino]methyl]anthracen-9-yl]methylamino]propanoate Chemical compound C1=CC=C2C(CNCCC(=O)OC(C)(C)C)=C(C=CC=C3)C3=C(CNCCC(=O)OC(C)(C)C)C2=C1 OVGSAMHLIFJBCO-UHFFFAOYSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- GUPIKZAAELPHQW-UHFFFAOYSA-N 1-ethylanthracene Chemical compound C1=CC=C2C=C3C(CC)=CC=CC3=CC2=C1 GUPIKZAAELPHQW-UHFFFAOYSA-N 0.000 description 1
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- BDXOIOHRHPQRJK-UHFFFAOYSA-N 2-methyl-n-[3-[(1-methylanthracen-9-yl)amino]propyl]prop-2-enamide Chemical compound C1=CC(C)=C2C(NCCCNC(=O)C(=C)C)=C(C=CC=C3)C3=CC2=C1 BDXOIOHRHPQRJK-UHFFFAOYSA-N 0.000 description 1
- RJKUSEIMRIQXLA-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxoanthracene-2-sulfonyl chloride Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(Cl)(=O)=O)=C2 RJKUSEIMRIQXLA-UHFFFAOYSA-N 0.000 description 1
- WNIFCLWDGNHGMX-UHFFFAOYSA-N 3-borono-5-nitrobenzoic acid Chemical compound OB(O)C1=CC(C(O)=O)=CC([N+]([O-])=O)=C1 WNIFCLWDGNHGMX-UHFFFAOYSA-N 0.000 description 1
- VFXXTYGQYWRHJP-UHFFFAOYSA-N 4,4'-azobis(4-cyanopentanoic acid) Chemical compound OC(=O)CCC(C)(C#N)N=NC(C)(CCC(O)=O)C#N VFXXTYGQYWRHJP-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PCVRSXXPGXRVEZ-UHFFFAOYSA-N 9-(chloromethyl)anthracene Chemical compound C1=CC=C2C(CCl)=C(C=CC=C3)C3=CC2=C1 PCVRSXXPGXRVEZ-UHFFFAOYSA-N 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 0 CCNC1(COC(c2ccccc2CC(CCOCCO)Cc2c(cccc3)c3c(C*(CCOCC*)Cc3c(*(OC4)OCC4(NI)NI=C)cccc3)c3c2cccc3)OC1)NI Chemical compound CCNC1(COC(c2ccccc2CC(CCOCCO)Cc2c(cccc3)c3c(C*(CCOCC*)Cc3c(*(OC4)OCC4(NI)NI=C)cccc3)c3c2cccc3)OC1)NI 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ILKQGIXDKWCJDI-UHFFFAOYSA-N OBO.C1=CC=CC2=CC3=CC=CC=C3C=C21 Chemical compound OBO.C1=CC=CC2=CC3=CC=CC=C3C=C21 ILKQGIXDKWCJDI-UHFFFAOYSA-N 0.000 description 1
- PKXGDSSAPAVORG-UHFFFAOYSA-N ON1C(=O)CCC1=O.OC(=O)C1CCCCC1 Chemical compound ON1C(=O)CCC1=O.OC(=O)C1CCCCC1 PKXGDSSAPAVORG-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- MYVJCOQGXCONPE-UHFFFAOYSA-N [2-(bromomethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1CBr MYVJCOQGXCONPE-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WMUSCAGYLQKRCI-UHFFFAOYSA-N anthracene;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC=CC2=CC3=CC=CC=C3C=C21 WMUSCAGYLQKRCI-UHFFFAOYSA-N 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 125000005621 boronate group Chemical group 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002143 fast-atom bombardment mass spectrum Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- KUCOHFSKRZZVRO-UHFFFAOYSA-N terephthalaldehyde Chemical compound O=CC1=CC=C(C=O)C=C1 KUCOHFSKRZZVRO-UHFFFAOYSA-N 0.000 description 1
- ZJXHVYSDMUKUCA-UHFFFAOYSA-N tert-butyl 3-aminopropanoate Chemical compound CC(C)(C)OC(=O)CCN ZJXHVYSDMUKUCA-UHFFFAOYSA-N 0.000 description 1
- DOMTZTVJNZKUNX-UHFFFAOYSA-N tert-butyl 3-aminopropanoate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CCN DOMTZTVJNZKUNX-UHFFFAOYSA-N 0.000 description 1
- JXGKVWUGUBRUFJ-UHFFFAOYSA-N tert-butyl 4-amino-2-(2-aminoethyl)butanoate Chemical compound C(C)(C)(C)OC(=O)C(CCN)CCN JXGKVWUGUBRUFJ-UHFFFAOYSA-N 0.000 description 1
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
- RVZPDKXEHIRFPM-UHFFFAOYSA-N tert-butyl n-(6-aminohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN RVZPDKXEHIRFPM-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
Definitions
- the present invention relates to the detection of glucose in samples which may also contain potential interfering compounds, such as ⁇ -hydroxy acids or ⁇ - di etones .
- U.S. Patent 5,503,770 describes a fluorescent boronic acid-containing compound that emits fluorescence of a high intensity upon binding to saccharides, including glucose.
- the fluorescent compound has a molecular structure comprising a fluorophore, at least one phenylboronic acid moiety and at least one amine-providing nitrogen atom where the nitrogen atom is disposed in the vicinity of the phenylboronic acid moiety so as to interact intramolecularly with the boronic acid. Such interaction thereby causes the compound to emit fluorescence upon saccharide binding. See also T. James, et al . , J. Am . Chem . Soc . 117 (35) : 8982-87 (1995).
- anthrylboronic acid-containing compound for detecting blood glucose
- J. Yoon, et al . , J. Am . Chem . Soc . 114:5874-5875 (1992) describe that anthrylboronic acid can be used as a fluorescent chemosensor for signaling carbohydrate binding, including binding of glucose and fructose.
- compounds which interact with glucose in the manner described above also have a tendency to interact with other compounds having hydroxyl groups, thus reducing the specificity of a glucose assay, especially when assaying physiological samples which may contain interfering amounts of lactate, acetoacetate, etc.
- the present invention is directed to a method for detecting the presence or concentration of glucose in a sample which may also contain an ⁇ -hydroxy acid or a ⁇ -diketone, which comprises: a) exposing the sample to a compound having at least two recognition elements for glucose, oriented such that the interaction between the compound and glucose is more stable than the interaction between the compound and the ⁇ -hydroxy acid or ⁇ -diketone, said compound also containing a detectable moiety having a detectable quality that changes in a concentration-dependent manner when said compound is exposed to glucose in said sample; and b) measuring any change in said detectable quality to thereby determine the presence or concentration of glucose in said sample, wherein the presence of the ⁇ - hydroxy acid or the ⁇ -diketone does not substantially interfere with said determination.
- the present invention is directed to a compound having the following structure
- R 2 are the same or different and are selected from the following: i) hydrogen; ii) a substituent to modify the pKa and hydrolytic stability of the R 8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
- -R 3 is hydrogen or a linking group capable of attachment to a solid support or a, polymeric matrix, said support or matrix optionally containing a detectable moiety;
- R 4 and R5 are the same or different and are selected from the following: i) hydrogen, ii) a substituent to modify the pKa and hydrolytic stability of the R 8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
- -each Z is independently carbon or nitrogen
- -R 6 and R 7 are the same or different and are i) linking groups having from zero to ten contiguous or branched carbon and/or heteroatoms, or ii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
- -R is selected from the following: i) an aliphatic and/or aromatic spacer containing from 1 to 10 contiguous atoms selected from the group consisting of carbon, oxygen, nitrogen, sulfur and phosphorus, ii) a detectable moiety, or iii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
- each Re is the same or different and is an optionally protected moiety which when unprotected is capable of interaction with the vicinal diol groups present in glucose; and -Rg and R 10 are the same or different, and are i) hydrogen, ii) a detectable moiety, iii) a group which is a) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety, and/or b) includes a functional • group capable of altering the physical properties of the compound; with the proviso that the indicator compound contains at least one detectable moiety associated therewith, either directly or as part of the solid support or polymeric matrix.
- the present invention is directed to a detection system which comprises a compound described above.
- Figure 1 illustrates the normalized fluorescence emission (I/Io @ 420 nm) of an indicator as described in Example 1.
- Figure 2 illustrates the normalized fluorescence emission (I/Io @ 428 nm) of an indicator as described in Example 2.
- Figure 3 illustrates the normalized fluorescence emission (I/Io @ 428 nm) of an indicator as described in Example 3.
- Figure 4 illustrates the normalized fluorescence emission (I/Io @ 427 nm) of an indicator as described in Example 4.
- Figure 5 illustrates the normalized fluorescence emission (I/Io @ 540 nm) of an indicator as described in Example 5.
- Figure 6 illustrates the absorbance spectra of an indicator as described in Example 6.
- Figures 7-8 illustrate the ratio of the absorbance (450 nm/530 nm) of an indicator as described in Example 6.
- Figure 9 illustrates the normalized fluorescence emission (I/Io at 550 nm) of an indicator as described in Example 6.
- Figure 10 illustrates the fluorescence spectrum, in the absence of glucose and in the presence of 100 mM glucose, of an indicator as described in Example 6.
- Figure 11 illustrates the normalized fluorescence emission (I/Io at 550 nm) , in the presence of glucose and lactate, of an indicator as described in Example 6.
- Figure 12 illustrates the normalized fluorescence emission (I/Io at 525 nm) of an indicator exposed to glucose as described in Example 10.
- Figure 13 illustrates the normalized fluorescence emission (I/Io at 530 nm) of an indicator exposed to lactate as described in Example 10.
- Figure 14 shows the relative fluorescence emission (I @ 430 nm) of an indicator exposed to glucose and lactate as described in Example 11.
- Figure 15 shows the relative fluorescence emission (I @ 430 nm) of an indicator exposed to glucose and lactate as described in Example 12.
- Figure 16 illustrates the fluorescence of an indicator exposed to glucose and lactate as described in Example 13.
- the present invention provides a way to detect the presence or concentration of glucose in a sample which may also contain interfering compounds, such as ⁇ -hydroxy acids or ⁇ -diketones.
- interfering compounds such as ⁇ -hydroxy acids or ⁇ -diketones.
- Such potentially interfering compounds include lactate, acetoacetate, ⁇ - hydroxy butyric acid, etc.
- the present invention is carried out using an indicator compound which is capable of recognizing glucose in a sample, .but which is less likely to recognize interfering compounds in the sample.
- the indicator compound has at least two recognition elements for glucose, oriented such that the interaction between the indicator compound and glucose is more stable than the interaction between the indicator compound and the interfering compounds.
- Suitable recognition elements include moieties which are capable of a preferably reversible interaction with glucose, especially with the diol groups present in glucose.
- recognition elements include boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, etc.
- recognition elements containing boron are well known, and include neopentyl glycol, pinacol, etc.
- the capped recognition element is decapped in the medium in which the compound is to be used (see, e . g. , Example 5).
- the recognition elements are preferably spaced on the indicator compound a suitable distance from each other so as to allow at least two of the recognition elements to interact with a glucose molecule, resulting in increased specificity.
- the recognition elements may have a spacer of up to about 30 atoms between them.
- the recognition elements are oriented such that they are capable of being about 6A apart when interacting with glucose.
- the indicator compounds of the present invention have a detectable quality that changes in a concentration- dependent manner when the compound is exposed to a sample containing glucose.
- the indicator compound may include a luminescent (fluorescent or phosphorescent) or chemiluminescent moiety, an absorbance based moiety, etc .
- the indicator compound may include an energy donor moiety and an energy acceptor moiety, each spaced such that there is a detectable change when the indicator compound interacts with glucose.
- the indicator compound may include a fluorophore and a quencher, configured such that the fluorophore is quenched by the quencher when glucose is absent.
- the indicator undergoes a configurational change which causes the quencher to move sufficiently distant from the fluorophore so that fluorescence is emitted.
- the fluorophore and quencher may be configured such that in the absence of glucose, they are sufficiently separated and the fluorophore emits fluorescence; upon interaction with glucose, the fluorophore and quencher are moved in sufficient proximity to cause quenching.
- the indicator may include a moiety such as a fluorophore capable of interacting with the recognition element or another moiety spatially disposed with respect to the recognition element such that in the absence of glucose, the fluorophore emits fluorescence.
- a moiety such as a fluorophore capable of interacting with the recognition element or another moiety spatially disposed with respect to the recognition element such that in the absence of glucose, the fluorophore emits fluorescence.
- the glucose competes with the interaction between the fluorophore and the recognition element, or the interaction between the fluorophore and the other moiety spatially disposed with respect to the recognition element, causing a reduction in fluorescence.
- Example 6 An example of that concept is illustrated in Example 6.
- the indicator may be chosen such that the fluorophore emits no fluorescence, or a relatively low level of fluorescence, when the fluorophore interacts with the recognition element or another moiety spatially disposed with respect to the recognition element in the absence of glucose.
- the glucose competes with the interaction between the fluorophore and the recognition element, or the interaction between the fluorophore and the other moiety spatially disposed with respect to the recognition element, causing an increase in fluorescence.
- Other detectable moieties include those whose fluorescence is affected by glucose interaction via photoinduced electron transfer or inductive effects. These include the lanthanide chelates disclosed in copending U.S. Application Serial No.
- the detectable quality is a detectable spectral change, such as changes in absorptive characteristics (e.g., absorbtivity and/or spectral shift), in fluorescent decay time (determined by time domain or frequency domain measurement) , fluorescent intensity, fluorescent anisotropy or polarization; a spectral shift of the emission spectrum; a change in time-resolved anisotropy decay (determined by time domain or frequency domain measurement) , etc.
- absorptive characteristics e.g., absorbtivity and/or spectral shift
- fluorescent decay time determined by time domain or frequency domain measurement
- fluorescent intensity fluorescent anisotropy or polarization
- a spectral shift of the emission spectrum e.g., a change in time-resolved anisotropy decay (determined by time domain or frequency domain measurement) , etc.
- the indicator compounds of the present invention if soluble, may be used directly in solution if so desired. On the other hand, if the desired application so requires, the indicator compounds may be immobilized
- the indicator compound is entrapped within, for example, another polymer
- the entrapping material preferably should be sufficiently permeable to glucose to allow suitable interaction between glucose and the indicator compound.
- the indicator compounds are sparingly soluble or insoluble in water, yet detection in an aqueous medium is desired, the indicator compound may be co-polymerized with a hydrophilic monomer to form a hydrophilic macromolecule as described in co-pending U.S. application Serial No. 09/632,624, filed August 4, 2000, the contents of which are incorporated herein by reference.
- Preferred indicator compounds have the following structure:
- R 2 are the same or different and are selected from the following: i) hydrogen; ii) a substituent to modify the pKa and hydrolytic stability of the R 8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
- -R 3 is hydrogen or a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety
- -R 4 and R5 are the same or different and are selected from the following: i) hydrogen, ii) a substituent to modify the pKa and hydrolytic stability of the R 8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
- -each Z is independently carbon or nitrogen;
- -R 6 and R 7 are the same or different and are i) linking groups having from zero to ten contiguous or branched carbon and/or heteroatoms, or ii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
- -R is selected from the following: i) an ali
- each R e is the same or different and is an optionally protected moiety which when unprotected is capable of interaction with the vicinal diol groups present in glucose;
- -R 9 and Rio are the same or different, and are i) hydrogen, ii) a detectable moiety, iii) a group which is a) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety, and/or b) includes a functional group capable of altering the physical properties of the compound; with the proviso that the indicator compound contains at least one detectable moiety associated therewith, either directly or as part of the solid support or polymeric matrix.
- Suitable groups for modifying the pKa and hydrolytic stability of the R 8 moieties would be readily apparent to one of ordinary skill, and include groups such as halogen; nitro; amino; halogen substituted alkyl; optionally substituted carboxyl; acyl; keto; nitrile; amide; ester; alkoxy; etc .
- Suitable linking groups for any substituent may include groups from about 1 to about 20 contiguous atoms, which may be branched or substituted and which may include one or more heteroatoms, which terminate in a functional group capable of further reaction or attachment to a polymer or support.
- suitable linking groups include alkyl; aryl; acyl; polyamide; polyether; all optionally substituted, and combinations thereof.
- Rg and Rio may urther include functional groups capable of altering the physical properties of the compound, such as solubility, pKa, etc.
- these include optionally substituted carboxylates, amino groups, quartenary ammonium groups, sulfonates, PEG, etc.
- suitable linking groups include those listed above.
- Suitable detectable moieties include those defined above.
- Rs is preferably selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, and combinations thereof.
- the present compounds and detection systems may be in polymeric form.
- an integral compound containing recognition elements and detectable moiety
- the integral compound in monomeric form could be polymerized or co- polymerized with another suitable monomer to form a polymer.
- two separate monomeric components e . g. , one containing the recognition elements, and one containing a detectable moiety
- the resulting polymer contains all necessary elements of the system (see Example 6).
- the indicator compounds can be used to detect sub-levels or supra-levels of glucose in physiological buffers or fluids, such as blood, plasma, serum, interstitial fluid, cerebrospinal fluid, urine, saliva, intraocular fluid, lymph, tears, or sweat, thus providing valuable information for diagnosing or monitoring such diseases as diabetes and adrenal insufficiency.
- physiological buffers or fluids such as blood, plasma, serum, interstitial fluid, cerebrospinal fluid, urine, saliva, intraocular fluid, lymph, tears, or sweat, thus providing valuable information for diagnosing or monitoring such diseases as diabetes and adrenal insufficiency.
- Uses for the present invention in agriculture include detecting levels of glucose in soybeans and other agricultural products. Glucose must be carefully monitored in critical harvest decisions for such high value products as wine grapes. As glucose is the most expensive carbon source and feedstock in fermentation processes, glucose monitoring for optimum reactor feed rate control is important in power alcohol production. Reactor mixing and control of glucose concentration also is critical to quality control during production of soft drinks and fermented beverages, which consumes the largest amounts of glucose and fermentable (vicinal diol) sugars internationally.
- the indicator compounds incorporate fluorescent indicator substituents, various detection techniques also are known in the art. For example, the compounds of the invention can be used in fluorescent sensing devices (e.g., U.S. Patent No.
- U.S. Patent 5,517,313 the disclosure of which is incorporated herein by reference, describes a fluorescence sensing device in which the compounds of the present invention can be used to determine the presence or concentration of glucose in a liquid medium.
- the sensing device comprises a layered array of a fluorescent indicator molecule-containing matrix (hereafter "fluorescent matrix”), a high-pass filter and a photodetector .
- fluorescent matrix a fluorescent indicator molecule-containing matrix
- a high-pass filter a high-pass filter
- a photodetector a photodetector
- a light source preferably a light-emitting diode (“LED”), is located at least partially within the indicator material, or in a waveguide upon which the indicator matrix is disposed, such that incident light from the light source causes the indicator molecules to fluoresce.
- LED light-emitting diode
- the high-pass filter allows emitted light to reach the photodetector, while filtering out scattered incident light from the light source.
- the fluorescence of the indicator molecules employed in the device described in U.S. Patent 5,517,313 is modulated, e.g., attenuated or enhanced, by the local presence of glucose.
- the material which contains the indicator molecule is permeable to the analyte.
- the analyte can diffuse into the material from the surrounding test medium, thereby affecting the fluorescence emitted by the indicator compounds.
- the light source, indicator compound-containing material, high-pass filter and photodetector are configured such that at least a portion of the fluorescence emitted by the indicator compounds impacts the photodetector, generating an electrical signal which is indicative of the concentration of glucose in the surrounding medium.
- sensing devices also are described in U.S. Patent Nos. 5,910,661, 5,917,605 and 5,894,351, all incorporated herein by reference.
- the compounds of the present invention can also be used in an implantable device, for example to continuously monitor blood glucose levels in vivo .
- Suitable devices are described in, for example, co- pending U.S. Patent Application Serial No. 09/383,148 filed August 26, 1999, as well as U.S. Patent Nos. 5,833,603, 6,002,954 and 6,011,984, all incorporated herein by reference.
- Example 1 Water soluble copolymer of anthracene derivative and MAPTAC
- TLC Merck silica gel 60 plates, • Rf 0.36 with 90/10 CH 2 C1 2 /CH 3 0H, see with UV (254/366), ninhydrin stain.
- the solution was purged with argon gas for 5 minutes and then heated to 60°C in the dark for 18 hours. At this time, the viscous solution was cooled to 25°C, diluted with 5 mL water and dialyzed through a cellulose ⁇ acetate membrane (MWCO 3500) against 3 x 4 L of water. The dialyzed material was concentrated to dryness to yield 0.339 g (68%) of a yellow glassy solid.
- MWCO 3500 cellulose ⁇ acetate membrane
- Example 2 Modulation of bis-boronate-indicator covalently attached to water-soluble polymer by glucose and potential physiological inter erences .
- reaction mixture was filtered and concentrated by rotary evaporation.
- the residue was purified by alumina column chromatography (50 g activated neutral alumina, 0-4% CH 3 0H/CH 2 C1 2 ) to yield 0.150 g (47%) of a yellow solid.
- FIG. 2 shows the normalized fluorescence emission (I/Io @ 428 nm) of a 1.5 mg/mL solution of anthracene bis boronate-TMAMA (1:50 mole ratio) copolymer in PBS containing a) 0-20 mM glucose; b) 0-20 mM lactate; c) 0-20 mM lithium acetoacetate.
- TLC Merck silica gel 60 plates, Rf 0.33 with 95/5 CH 2 C1 2 /CH 3 0H, see with UV (254/366) .
- FIG. 3 shows the fluorescence (at 428 nm) of 75 ⁇ M solutions of bis carboxylate bis-boronate- anthracene indicator in PBS containing a) 0-10 mM glucose, 0 mM lactate; b) 0-10 mM glucose, 2 mM lactate; c) 0-10 mM glucose, 5 mM lactate.
- Spectra were recorded using a Shimadzu RF-5301 spectrafluorometer with excitation @365 nm; excitation slits at 1.5 nm; emission slits at 1.5 nm; ambient temperature. All points measured in triplicate, with ⁇ 1 SD error bars included. The presence of lactate did not substantially affect the fluorescence modulation of the indicator by glucose.
- TLC Merck basic alumina plates, Rf 0.31 with 90/10 CH 2 C1 2 /CH 3 0H, see with UV (254/366) .
- reaction mixture was concentrated in va cuo and the residue was purified by alumina chromatography (200 g activated neutral alumina, 0-2% CH 3 0H/CH 2 C1 2 ) to yield 0.465 g (39%) of a very viscous yellow oil.
- TLC Merck basic alumina plates, Rf 0.59 with 90/10 CH 2 C1 2 /CH 3 0H, see with UV (254/366) .
- PBS phosphate buffered saline
- FIG. 4 shows the normalized fluorescence emission (I/Io @ 427 nm) of a hydrogel containing the glucose recognition molecule of this example in 10 mM PBS, pH 7.4 containing 0.2% NaN 3 and 1 mM EDTA containing various amounts of sodium-L-lactate, lithium acetoacetate or ⁇ -D-glucose.
- Solutions of 1, 5, 10 and 20 mM sodium L-lactate [Aldrich] , 5, 10 and 20 mM lithium acetoacetate [Aldrich], and 1, 2, 4, 5, 10, and 20 mM ⁇ -D-glucose were prepared in 10 mM PBS, pH 7.4 containing 0.2% NaN 3 and 1 mM EDTA.
- the fluorescence of the copolymer was affected by the presence of glucose, but not by the presence of lactate or acetoacetate.
- TLC Merck silica gel 60 plates plates, Rf 0.17 with 98/2 CH 2 C1 2 /CH 3 0H, see with UV (254/366) .
- TLC Merck silica gel 60 plates, Rf 0.71 with 95/5 CH 2 C1 2 /CH 3 0H, see with UV (254/366) .
- the suspension was stirred at 25°C for 5 hours. At this time, the reaction mixture was concentrated and the residue dissolved in 50 mL water and extracted 3 x 50 mL ether. The combined organic extracts were washed 2 x 50 mL water. The combined aqueous extracts were extracted 2 x 50 mL ether. The combined organic extracts were dried over Na 2 S0 4 , filtered and concentrated to yield 1.35 g (81%) of a viscous oil.
- TLC Merck silica gel 60 plates plates, Rf 0.58 with 80/15/5 CH 2 Cl 2 /CH 3 OH/iPrNH 2 , see with ninhydrin stain, UV (254/366) .
- N-2- [6-N (N-4-dimethylaminobenzyl) aminohexyl] amino- ethyl) -4-butylamino-l , 8-naphthalimide To a suspension of N- (2-oxoethyl) -4-butylamino-l, 8- naphthalimide (0.346 g, 1.11 mmol) in 25 mL anhydrous MeOH was added a solution of N- (4-dimethylamino- benzyl) -1, 6-diaminohexane (0.554 g, 2.22 mmol, 2.00 equiv.) and acetic acid (0.067 g, 1.1 mmol, 1.0 equiv.) in 20 mL anhydrous MeOH.
- the crude material was purified by silica gel chromatography (35 g flash grade gel, 0-50% CH 3 0H/CH 2 C1 2 , then 45/50/5 CH 3 OH/CH 2 Cl 2 /iPrNH 2 ) to yield 0.190 g (32%) of diamine product.
- TLC Merck neutral alumina plates, Rf 0.62 with 80/20 CH 2 C1 2 /CH 3 0H, see with UV (254/366') .
- the free bis boronic acid product used in glucose studies results from dissolution of N-2- [ 6-N- (N-4- dimethyl-aminobenzyl ) -6-N- [2- ( 5 , 5-dimethylborinan-2 - yl ) benzyl ] amino-hexyl ] - [ 2- ( 5 , 5-dimethylborinan-2- yl ) benzyl ] aminoethyl-4 - butylamino-1 , 8 -naphthalimide in the MeOH/PBS buffer system .
- FIG. 1 Modulation of fluorescence with glucose and lactate .
- Figure 5 shows the normalized fluorescence emission (I/Io @ 535 nm) of 0.015 mM solutions of the indicator compund in 70/30 MeOH/PBS containing a) 0-20 mM glucose; b) 0-20 mM lactate.
- Spectra were recorded using a Shimadzu RF-5301 spectrafluorometer with excitation @ 450 nm; excitation slits at 1.5 nm; emission slits at 1.5 nm; ambient temperature. Error bars are standard deviation with triplicate values for each data point.
- the fluorescence of the indicator was affected by the presence of glucose, but not substantially affected by the presence of lactate.
- Example 6 Effect of glucose or lactate on acrylamide gel containing N- [3- (methacrylamido)propyl] -3, 4-dihydroxy-9 , 10-dioxo-2- anthracenesulfonamide (Alizarin Red S monomer) and ⁇ , ⁇ ' -bis [N- [2- (5 , 5-dimethylborinan-2-yl)benzyl] -N- [3-
- N- (3-aminopropyl) methacrylamide hydrochloride salt (3.00 g, 16.8 mmole, 2.21 equiv.), DIEA (6.5 g, 8.8 mL, 50 mmole, 6.6 equiv.), terephthaldicarboxaldehyde (1.02 g, 7.60 mmole) and Na 2 S0 4 (10.7 g, 75.3 mmole, 9.91 equiv.) in 75 mL anhydrous MeOH was stirred in the dark at 25DC for 18 hours. At this time, more Na 2 S0 4 (10.7 g, 75.3 mmole, 9.91 equiv.) was added and stirring continued for 6 hours longer.
- o,oc -bis [N- [2- (5, 5-dimethylborinan-2-yl)benzyl] - N- [3- (methacrylamido) propylamino] -1 , 4-xylene .
- This formulation was placed in a glove box purged with nitrogen along with a mold constructed from glass microscope slides and 100 micron stainless steel spacer.
- An aqueous solution of N,N,N ' ,N' -tetramethylethylenediamine (40 ⁇ L, 5% wt . ) was added to the monomer solution to accelerate polymerization and the final formulation was poured into a glass mold.
- the modulation of the absorbance of the indicator hydrogel (which contains two recognition elements) prepared in this example by glucose and lactate was determined.
- the acrylamide gel was mounted in PMMA cell in the same way as described in Example 4.
- Absorbance measurement for each glucose or lactate concentration was conducted in triplicate.
- FIG. 6 shows the absorbance spectra for acrylamide gel (30%) containing 4 mM Alizarin Red S monomer and 44 mM bis boronic acid monomer with and without glucose.
- Figure 7 shows the effect of glucose on absorbance of acrylamide gel (30%) containing 4 mM Alizarin Red S monomer and 44 mM bis boronic acid monomer.
- Figure 8 shows the effect of sodium lactate on absorbance of acrylamide gel (30%) containing 4 mM Alizarin. Red S monomer and 44 mM bis boronic acid monomer.
- the absorbance of the indicator was affected by the presence of glucose, but not substantially affected by the presence of lactate.
- Example 6 except that 1.9 mg of N- [3- (methacrylamido) - propyl] -3, 4-dihydroxy-9, 10-dioxo-2-anthracenesulfonamide and 35 mg of ⁇ , ' -bis [N- [2- (5, 5-dimethylborinan-2-yl) - benzyl] -N- [3- (methacrylamido) propylamino] -1, 4-xylene were used) was determined.
- the experiment was conducted in a Shimadzu RF-5301 PC spectrofluorimeter equipped with a variable temperature attachment (excitation at 470 nm, slits 3/10 nm, high sensitivity) .
- the acrylamide gel was attached to a piece of a glass slide which was glued in a PMMA fluorescence cell at a 45° angle.
- the Alizarin Red S and bis-boronate recognition element monomers are capable of reversible reaction with each other to form a boronate ester.
- the boronate ester molecule formed in this reversible reaction is fluorescent, while the Alizarin Red S monomer by itself displays virtually no fluorescence emission in aqueous solution and in organic solvents, such as MeOH.
- Alizarin Red S changes its optical properties, such as absorbance and quantum yield of fluorescence, for example.
- a solution of Alizarin Red S with monomer functionality and glucose recognition element with monomer functionality can be prepared together with a hydrogel monomer and a crosslinker. Copolymerization of this mixture produces a hydrogel material which is diffusable to various small and medium size molecules; thus it is capable of analyte detection and quantitation.
- An analyte such as glucose for example, would diffuse inside the hydrogel matrix and displace the reporter molecule previously bound to the recognition element. This event causes a change in the optical properties of the hydrogel film since it now contains a greater number of reporter molecules unbound to the recognition element.
- the modulation of the fluorescence of the indicator compound (which contains two recognition elements) prepared in this example by glucose and lactate was also determined.
- the experiment was conducted in a Shimadzu RF-5301 PC spectrofluorimeter equipped with a variable temperature attachment (excitation at 470 nm, slits 5/10 nm, low sensitivity) .
- the acrylamide gel was attached to a piece of a glass slide which was glued in a PMMA fluorescence cell at a 45° angle.
- TLC Merck silica gel 60 plates, Rf 0.72 with 70/30 CH 2 C1 2 /CH 3 0H, see with UV (254/366), ninhydrin stain.
- reaction mixture was filtered and washed with 2 x 40 mL of NaHC0 3 (saturated aqueous solution) .
- the organic extract was dried over anhydrous Na 2 S0 4 , filtered and concentrated to yield a sticky orange solid which was purified by alumina chromatography (50 g activated neutral alumina, 0-5% CH 3 0H/CH 2 C1 2 ) to yield 0.364 g (20%) of an orange solid.
- reaction mixture was concentrated initially by rotary evaporation, then using a vacuum pump to remove DIEA.
- the residue was purified by alumina column chromatography (40 g activated neutral alumina, 0- 10% CH 3 0H/CH 2 C1 2 ) to yield 0.299 g (46%) of a yellow orange solid.
- This compound may be co-polymerized with a suitable monomer as described previously, deprotected, and used to detect glucose.
- reaction mixture was filtered and concentrated by rotary evaporation.
- the residue was purified by alumina column chromatography (30 g activated neutral alumina, 0-2% CH 3 0H/CH 2 C1 2 ) to yield 0.030 g (26%) of a yellow solid.
- This compound may be co-polymerized with a suitable monomer as described previously, deprotected, and used to detect glucose.
- TLC Merck basic alumina plates, Rf 0.67 with 95/5 CH 2 C1 2 /CH 3 0H, see with UV (254/366) .
- N-t-Boc-ethylenediamine (Fluka, 1.6 g, 10 mmole) and 4-bromo-l, 8-naphthalic anhydride (Aldrich, 2.77 g, 10 mmole) were combined with 60 ml of anhydrous ethanol, the suspension was stirred at 60°C for 20 hours, cooled to room temperature, and filtered. The obtained solid was washed with 30 ml of cold EtOH and dried under vacuum. Yield 3.84 g (91%).
- N-Methylethylenediamine (1.48 g, 20 mmole) was combined with 2 ml of l-methyl-2-pyrrolidinone (NMP) followed by addition of N-2- (tert- butoxycarbonyl) aminoethyl-4-bromonaphthalene-l, 8- dicarboximide (0.35 g, 0.845 mmole). The resulting solution was stirred at 45°C for 40 hours after which NMP and N-methylethylenediamine were evaporated under vacuum.
- NMP l-methyl-2-pyrrolidinone
- N-aminoethyl-4- (N' -aminoethylene-N' ' - [2- (borono)benzyl]methylamino) naphthalene-1 , 8- dicarboximide trifluoroacetic acid salt: N-2- (tert-butoxycarbonyl) aminoethyl-4- (N' - methylaminoethylamino) naphthalene-1, 8-dicarboximide (0.3 g, 0.73 mmole), 2-bromomethylphenyl boronic acid, pinacol ester (0.6 g, 2 mmole), N, N-diisopropyl-N-ethylamine (1.3 ml, 8 mmole), and 10 ml of CH 2 C1 2 were combined.
- the reaction mixture was subsequently stirred in the dark at ambient temperature for 4 days. At this time, the CHC1 3 was evaporated and the residue was dissolved in 100 mL ether. The organic layer was extracted with 8 x 125 mL sat'd aqueous NaHC0 3 and 5 x 200 mL phosphate buffer (0.4 M, pH 7.0). The pH of the combined phosphate buffer washes was adjusted to pH 11 by addition of Na 2 C0 3 (sat'd aqueous solution), followed by extraction with 5 x 300 mL CH 2 C1 2 . The combined organic layers were concentrated and the residue dissolved in 5 mL of a 20% solution of TFA in CH 2 C1 2 . The mixture was stirred at ambient temperature for 2 hours .
- reaction mixture was extracted with 4 x 10 mL sat'd aqueous NaHC0 3 .
- the pH of the combined aqueous layers was adjusted to pH 11 by addition of Na 2 C0 3 (sat'd aqueous solution), followed by extraction with 4 x 75 mL CH 2 C1 2 .
- the combined organic extracts were dried over anhydrous Na 2 S0 4 , filtered and concentrated in vacuo to yield 0.068 g (27%) of product.
- TLC a) Merck Silica Gel 60 plates, Rf 0.16 with 70/30 CH 2 C1 2 /CH 3 0H, see with UV (254/366), prior to deprotection; Rf 0.27 with 85/14.5/0.5 CH 2 Cl 2 /CH 3 OH/iPrNH 2 , see with UV (254/366), final product .
- reaction mixture was concentrated in vacuo and the residue dissolved in 105 mL of a solution of 90/15 ether/ CH 2 C1 2 .
- the organic layer was extracted with 4 x 225 mL phosphate buffer (0.4 M, pH 7.0).
- the pH of the combined phosphate buffer washes. was adjusted to pH 11 by addition of Na 2 C0 3 (sat'd aqueous solution), followed by extraction with 6 x 500 mL CH 2 C1 2 .
- the combined organic layers were dried over anhydrous Na 2 S0 4 , filtered and concentrated in va cuo to yield 1.2 g (60%) of product.
- a solution of N, N-dimethylacrylamide (40% wt . ) and N,N'- methylenebisacrylamide (0.8% wt . ) in phosphate buffer, pH 7.4, 200 mM was prepared.
- FIG. 14 shows the relative fluorescence emission (I @ 430 nm) of the hydrogel film in PBS (pH 7.4 containing 0.02% NaN 3 and 1 mM EDTA) containing 0 to 20 mM ⁇ -D-glucose, 0 to 10 mM L-sodium lactate, and 0-20 mM ⁇ - D-glucose in the presence of 4 mM L-sodium lactate.
- the reaction mixture was subsequently stirred in the dark at 30 °C for 88 hours. At this time, the CHC1 was evaporated and the residue was dissolved in 500 mL ether. The solution was stirred for 1 hour at which time salts had precipitated from solution.
- the ether solution was filtered and subsequently extracted with 10 x 350 mL sat'd aqueous NaHC0 3 .
- the ether layer was further extracted with 6 x 350 mL phosphate buffer (0.2 M, pH 6.5). The pH of the combined phosphate buffer washes was adjusted to pH 11-12 by addition of Na 2 C0 3 (sat'd aqueous solution), followed by extraction with 6 x 500 mL CH 2 C1 2 .
- the combined organic layers were dried over anhydrous Na 2 S0 4 , filtered and concentrated in vacuo to yield an oily crude product.
- the crude product was purified by silica gel chromatography (50 g flash grade silica gel, 0-5% MeOH/CH 2 Cl 2 step gradient) to yield 2.04 g of a sticky yellow solid (23%) .
- TLC Merck Silica Gel 60 plates, Rf 0.29 with 90/10 CH 2 C1 2 /CH 3 0H, see with UV (254/366) and ninhydrin stain.
- the ether layer was extracted with 3 x 125 mL phosphate buffer (0.2 M, pH 7.0), dried over anhydrous Na 2 S0 4 , filtered and concentrated in vacuo to yield a crude product. The residue was triturated with hexanes to yield 2.14 g (76%) of a white solid.
- FIG. 15 shows the relative fluorescence emission (I @ 430 nm) of the hydrogel film in PBS (pH 7.4 containing 0.02% NaN 3 and 1 mM EDTA) containing 0 to 20 mM ⁇ -D-glucose, 0 to 10 mM L- sodium lactate, and 0-20 mM glucose in the presence of 3 mM L-sodium lactate.
- the hydrogel film (100 ⁇ m thickness, 8 mm diameter disk) was mounted in a PMMA cuvette at a 45° angle.
- N- (6-Aminohexyl) -anthracene-9-carboxamide hydrochloric acid salt 9-Anthracenoyl chloride (1.3 g, 5.4 mmole) in 50 ml of anhydrous CH 2 C1 2 was added dropwise to 11.6 g of hexamethylenediamine (100 mmole) in 100 ml of CH 2 C1 2 at 0°C. The solution was stirred at 0°C for 1 hour then allowed to warm to room temperature and stirred overnight. The solvent was evaporated and 200 ml of water was added to the residue. This mixture was sonicated and stirred for 1 hour then filtered. The filtered solid was dried under vacuum for 24 hours.
- Aqueous ammonium persulfate (20 ⁇ L, 5% wt . ) was combined with the formulation.
- the resulting solution was placed in a glove box purged with nitrogen.
- An aqueous solution of N,N,N' ,N' -tetramethylethylenediamine (40 ⁇ L, 5% wt . ) was added to the monomer formulation to accelerate polymerization.
- PBS phosphate buffered saline
- the experiment was conducted in a Shimadzu RF-5301 PC spectrofluorimeter equipped with a variable temperature attachment. Excitation wavelength was set at 370 nm, slits 3/3 nm, low PMT sensitivity, emission was scanned from 400 to 600 nm. Glucose and L-sodium lactate concentrations were checked using YSI Model 2300 STAT plus glucose analyzer.
- the hydrogel film (100 ⁇ m thickness, round shape - 8 mm diameter) was mounted in a PMMA cuvette at 45° angle.
- PBS Phosphate buffered saline
- the compound may be synthesized as shown below: EXAMPLE 16 Alternate glucose indicator/monomer excited with visible light
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Compositions and methods for determining the presence or concentration of glucose in a sample which may also contain an alpha-hydroxy acid or a beta-diketone. The method uses a compound having at least two recognition elements for glucose, oriented such that the interaction between the compound and glucose is more stable than the interaction between the compound and the alpha-hydroxy acid or beta-diketone, such that the presence of the alpha-hydroxy acid or the beta-diketone does not substantially interfere with said determination.
Description
TITLE OF THE INVENTION
DETECTION OF GLUCOSE IN SOLUTIONS ALSO CONTAINING
AN ALPHA-HYDROXY ACID OR A BETA-DIKETONE
CROSS-REFERENCE TO RELATED APPLICATIONS The present application is a continuation-in-part of application Serial No. 10/029,184 filed December 28, 2001, which is a continuation-in-part of application
Serial No. 09/754,217 filed January 5, 2001 and claims the benefit of application Serial No. 60/363,885 filed March 14, 2002, application Serial No. 60/329,746 filed October 18, 2001 and application Serial No. 60/269,887 filed February 21, 2001.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable.
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the detection of glucose in samples which may also contain potential interfering compounds, such as α-hydroxy acids or β- di etones .
2. Description of the Related Art
The complexation of carbohydrates, including glucose, with phenylboronic acid has been known for a long time and the reversibility of that interaction has served as a basis for the chromatographic separation of sugars.
Specifically, in 1959, Lorand and Edwards reported association constants for aqueous associations of phenylboronic acid with many saturated polyols; binding interactions ranged from very weak (e.g., ethylene glycol, Kd=360 mM) to moderately strong { e . g. , glucose,
Kd=9.1 mM) . See J. Yoon, et al . , Bioorgani c and Medi cinal Chemistry 1(4):267-71 (1993). The binding mechanism is believed to occur through bonding of adjacent hydroxyl groups on glucose to hydroxyl groups on a boronate moiety.
U.S. Patent 5,503,770 (James, et al . ) describes a fluorescent boronic acid-containing compound that emits fluorescence of a high intensity upon binding to saccharides, including glucose. The fluorescent compound has a molecular structure comprising a fluorophore, at least one phenylboronic acid moiety and at least one amine-providing nitrogen atom where the nitrogen atom is disposed in the vicinity of the phenylboronic acid moiety so as to interact intramolecularly with the boronic acid. Such interaction thereby causes the compound to emit fluorescence upon saccharide binding. See also T. James, et al . , J. Am . Chem . Soc . 117 (35) : 8982-87 (1995).
Additionally, fluorescent sensors using an anthrylboronic acid-containing compound for detecting blood glucose are known in the art. For example, J. Yoon, et al . , J. Am . Chem . Soc . 114:5874-5875 (1992) describe that anthrylboronic acid can be used as a fluorescent chemosensor for signaling carbohydrate binding, including binding of glucose and fructose. Unfortunately, compounds which interact with glucose in the manner described above also have a tendency to interact with other compounds having hydroxyl groups, thus reducing the specificity of a glucose assay, especially when assaying physiological samples which may
contain interfering amounts of lactate, acetoacetate, etc. For example, some diabetic patients also develop lactic acidosis, in which blood lactate levels are greater than 5 mmol/liter. Thus, there remains a great need for glucose assays which are relatively insensitive to potentially interfering hydroxyl compounds, such as lactate.
BRIEF SUMMARY OF THE INVENTION In one aspect, the present invention is directed to a method for detecting the presence or concentration of glucose in a sample which may also contain an α-hydroxy acid or a β-diketone, which comprises: a) exposing the sample to a compound having at least two recognition elements for glucose, oriented such that the interaction between the compound and glucose is more stable than the interaction between the compound and the α-hydroxy acid or β-diketone, said compound also containing a detectable moiety having a detectable quality that changes in a concentration-dependent manner when said compound is exposed to glucose in said sample; and b) measuring any change in said detectable quality to thereby determine the presence or concentration of glucose in said sample, wherein the presence of the α- hydroxy acid or the β-diketone does not substantially interfere with said determination.
In another aspect, the present invention is directed to a compound having the following structure
wherein:
-Ri and R2 are the same or different and are selected from the following: i) hydrogen; ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-R3 is hydrogen or a linking group capable of attachment to a solid support or a, polymeric matrix, said support or matrix optionally containing a detectable moiety;
-R4 and R5 are the same or different and are selected from the following: i) hydrogen, ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-each Z is independently carbon or nitrogen;
-R6 and R7 are the same or different and are i) linking groups having from zero to ten contiguous or branched carbon and/or heteroatoms, or ii) a linking group capable of attachment to a solid
support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R is selected from the following: i) an aliphatic and/or aromatic spacer containing from 1 to 10 contiguous atoms selected from the group consisting of carbon, oxygen, nitrogen, sulfur and phosphorus, ii) a detectable moiety, or iii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-each Re is the same or different and is an optionally protected moiety which when unprotected is capable of interaction with the vicinal diol groups present in glucose; and -Rg and R10 are the same or different, and are i) hydrogen, ii) a detectable moiety, iii) a group which is a) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety, and/or b) includes a functional • group capable of altering the physical properties of the compound; with the proviso that the indicator compound contains at least one detectable moiety associated therewith, either directly or as part of the solid support or polymeric matrix.
In another aspect, the present invention is directed to a detection system which comprises a compound described above.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 illustrates the normalized fluorescence emission (I/Io @ 420 nm) of an indicator as described in Example 1.
Figure 2 illustrates the normalized fluorescence emission (I/Io @ 428 nm) of an indicator as described in Example 2.
Figure 3 illustrates the normalized fluorescence emission (I/Io @ 428 nm) of an indicator as described in Example 3.
Figure 4 illustrates the normalized fluorescence emission (I/Io @ 427 nm) of an indicator as described in Example 4. Figure 5 illustrates the normalized fluorescence emission (I/Io @ 540 nm) of an indicator as described in Example 5.
Figure 6 illustrates the absorbance spectra of an indicator as described in Example 6. Figures 7-8 illustrate the ratio of the absorbance (450 nm/530 nm) of an indicator as described in Example 6.
Figure 9 illustrates the normalized fluorescence emission (I/Io at 550 nm) of an indicator as described in Example 6.
Figure 10 illustrates the fluorescence spectrum, in the absence of glucose and in the presence of 100 mM glucose, of an indicator as described in Example 6.
Figure 11 illustrates the normalized fluorescence emission (I/Io at 550 nm) , in the presence of glucose and lactate, of an indicator as described in Example 6.
Figure 12 illustrates the normalized fluorescence emission (I/Io at 525 nm) of an indicator exposed to glucose as described in Example 10. Figure 13 illustrates the normalized fluorescence emission (I/Io at 530 nm) of an indicator exposed to lactate as described in Example 10.
Figure 14 shows the relative fluorescence emission (I @ 430 nm) of an indicator exposed to glucose and lactate as described in Example 11.
Figure 15 shows the relative fluorescence emission (I @ 430 nm) of an indicator exposed to glucose and lactate as described in Example 12.
Figure 16 illustrates the fluorescence of an indicator exposed to glucose and lactate as described in Example 13.
DETAILED DESCRIPTION OF THE INVENTION In one aspect, the present invention provides a way to detect the presence or concentration of glucose in a sample which may also contain interfering compounds, such as α-hydroxy acids or β-diketones. Such potentially interfering compounds include lactate, acetoacetate, β- hydroxy butyric acid, etc.
The present invention is carried out using an indicator compound which is capable of recognizing glucose in a sample, .but which is less likely to recognize interfering compounds in the sample. The indicator compound has at least two recognition elements for glucose, oriented such that the interaction between the indicator compound and glucose is more stable than the interaction between the indicator compound and the interfering compounds.
Suitable recognition elements include moieties which are capable of a preferably reversible interaction with glucose, especially with the diol groups present in glucose. Several such recognition elements are known, and preferably include boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, etc. Most preferred are recognition elements containing boron. It will be
understood that until use, the recognition elements may be capped with a protecting group. Such groups are well known, and include neopentyl glycol, pinacol, etc. In certain embodiments, the capped recognition element is decapped in the medium in which the compound is to be used (see, e . g. , Example 5).
The recognition elements are preferably spaced on the indicator compound a suitable distance from each other so as to allow at least two of the recognition elements to interact with a glucose molecule, resulting in increased specificity. In general, the recognition elements may have a spacer of up to about 30 atoms between them. Preferably, the recognition elements are oriented such that they are capable of being about 6A apart when interacting with glucose.
The indicator compounds of the present invention have a detectable quality that changes in a concentration- dependent manner when the compound is exposed to a sample containing glucose. Many such qualities are known and may be used in the present invention. For example, the indicator compound may include a luminescent (fluorescent or phosphorescent) or chemiluminescent moiety, an absorbance based moiety, etc . The indicator compound may include an energy donor moiety and an energy acceptor moiety, each spaced such that there is a detectable change when the indicator compound interacts with glucose. The indicator compound may include a fluorophore and a quencher, configured such that the fluorophore is quenched by the quencher when glucose is absent. In that situation, when glucose is present, the indicator undergoes a configurational change which causes the quencher to move sufficiently distant from the fluorophore so that fluorescence is emitted. Conversely, the fluorophore and quencher may be configured such that
in the absence of glucose, they are sufficiently separated and the fluorophore emits fluorescence; upon interaction with glucose, the fluorophore and quencher are moved in sufficient proximity to cause quenching. The configurational change concept is described in more detail in our co-pending application Serial No. 09/754,219, filed January 5, 2001, entitled "Detection of Analytes", incorporated herein by reference.
Alternatively, the indicator may include a moiety such as a fluorophore capable of interacting with the recognition element or another moiety spatially disposed with respect to the recognition element such that in the absence of glucose, the fluorophore emits fluorescence. Upon addition of glucose, the glucose competes with the interaction between the fluorophore and the recognition element, or the interaction between the fluorophore and the other moiety spatially disposed with respect to the recognition element, causing a reduction in fluorescence. An example of that concept is illustrated in Example 6. It will also be recognized that the indicator may be chosen such that the fluorophore emits no fluorescence, or a relatively low level of fluorescence, when the fluorophore interacts with the recognition element or another moiety spatially disposed with respect to the recognition element in the absence of glucose. Upon addition of glucose, the glucose competes with the interaction between the fluorophore and the recognition element, or the interaction between the fluorophore and the other moiety spatially disposed with respect to the recognition element, causing an increase in fluorescence. Other detectable moieties include those whose fluorescence is affected by glucose interaction via photoinduced electron transfer or inductive effects. These include the lanthanide chelates disclosed in
copending U.S. Application Serial No. 09/265,979 filed March 11, 1999 (and published as PCT International Application WO 99/46600 on September 16, 1999), incorporated herein by reference; polyaromatic hydrocarbons and their derivatives; coumarins; BoDiPy; dansyl; catechols; etc. Another class of moieties include those whose absorbance spectrum changes upon interaction of the indicator compound with glucose, including Alizarin Red, etc. Another class of moieties include those whose fluorescence is modulated by proximity effects, e . g. , energy donor/acceptor pairs such as dansyl/dabsyl, etc.
Preferably, the detectable quality is a detectable spectral change, such as changes in absorptive characteristics (e.g., absorbtivity and/or spectral shift), in fluorescent decay time (determined by time domain or frequency domain measurement) , fluorescent intensity, fluorescent anisotropy or polarization; a spectral shift of the emission spectrum; a change in time-resolved anisotropy decay (determined by time domain or frequency domain measurement) , etc.
The indicator compounds of the present invention, if soluble, may be used directly in solution if so desired. On the other hand, if the desired application so requires, the indicator compounds may be immobilized
(such as by mechanical entrapment or covalent or ionic attachment) onto or within an insoluble surface or matrix such as glass, plastic, polymeric materials, etc. When the indicator compound is entrapped within, for example, another polymer, the entrapping material preferably should be sufficiently permeable to glucose to allow suitable interaction between glucose and the indicator compound.
If the indicator compounds are sparingly soluble or insoluble in water, yet detection in an aqueous medium is desired, the indicator compound may be co-polymerized with a hydrophilic monomer to form a hydrophilic macromolecule as described in co-pending U.S. application Serial No. 09/632,624, filed August 4, 2000, the contents of which are incorporated herein by reference.
Preferred indicator compounds have the following structure:
wherein:
-Ri and R2 are the same or different and are selected from the following: i) hydrogen; ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-R3 is hydrogen or a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R4 and R5 are the same or different and are selected from the following: i) hydrogen, ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a
polymeric matrix, said support or matrix optionally containing a detectable moiety; -each Z is independently carbon or nitrogen; -R6 and R7 are the same or different and are i) linking groups having from zero to ten contiguous or branched carbon and/or heteroatoms, or ii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R is selected from the following: i) an aliphatic and/or aromatic spacer containing from 1 to 10 contiguous atoms selected from, the group consisting of carbon, oxygen, nitrogen, sulfur and phosphorus, ii) a detectable moiety, or iii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-each Re is the same or different and is an optionally protected moiety which when unprotected is capable of interaction with the vicinal diol groups present in glucose; and
-R9 and Rio are the same or different, and are i) hydrogen, ii) a detectable moiety, iii) a group which is a) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety, and/or b) includes a functional group capable of altering the physical properties of the compound; with the proviso that the indicator compound contains at least one detectable moiety associated therewith, either directly or as part of the solid support or polymeric matrix.
Suitable groups for modifying the pKa and hydrolytic stability of the R8 moieties would be readily apparent to one of ordinary skill, and include groups such as halogen; nitro; amino; halogen substituted alkyl; optionally substituted carboxyl; acyl; keto; nitrile; amide; ester; alkoxy; etc .
Suitable linking groups for any substituent may include groups from about 1 to about 20 contiguous atoms, which may be branched or substituted and which may include one or more heteroatoms, which terminate in a functional group capable of further reaction or attachment to a polymer or support. Examples of suitable linking groups include alkyl; aryl; acyl; polyamide; polyether; all optionally substituted, and combinations thereof.
Rg and Rio may urther include functional groups capable of altering the physical properties of the compound, such as solubility, pKa, etc. For example, these include optionally substituted carboxylates, amino groups, quartenary ammonium groups, sulfonates, PEG, etc. It will be understood that when any of the substituents is a detectable moiety, that could also include suitable linking groups which link the detectable moiety to the rest of the indicator compound. Suitable linking groups include those listed above. Suitable detectable moieties include those defined above.
Rs is preferably selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, and combinations thereof.
It will also be understood from the above definition that the present compounds and detection systems may be in polymeric form. Thus, an integral compound (containing recognition elements and detectable moiety)
could be linked to an existing polymer, or the integral compound in monomeric form could be polymerized or co- polymerized with another suitable monomer to form a polymer. Alternatively, two separate monomeric components [ e . g. , one containing the recognition elements, and one containing a detectable moiety) could be co-polymerized so that the resulting polymer contains all necessary elements of the system (see Example 6). Many uses exist for the indicator compounds of the present invention, including uses as indicators in the fields of energy, medicine and agriculture. For example, the indicator compounds can be used to detect sub-levels or supra-levels of glucose in physiological buffers or fluids, such as blood, plasma, serum, interstitial fluid, cerebrospinal fluid, urine, saliva, intraocular fluid, lymph, tears, or sweat, thus providing valuable information for diagnosing or monitoring such diseases as diabetes and adrenal insufficiency.
Medical/pharmaceutical production of glucose for human therapeutic application requires monitoring and control .
Uses for the present invention in agriculture include detecting levels of glucose in soybeans and other agricultural products. Glucose must be carefully monitored in critical harvest decisions for such high value products as wine grapes. As glucose is the most expensive carbon source and feedstock in fermentation processes, glucose monitoring for optimum reactor feed rate control is important in power alcohol production. Reactor mixing and control of glucose concentration also is critical to quality control during production of soft drinks and fermented beverages, which consumes the largest amounts of glucose and fermentable (vicinal diol) sugars internationally.
When the indicator compounds incorporate fluorescent indicator substituents, various detection techniques also are known in the art. For example, the compounds of the invention can be used in fluorescent sensing devices (e.g., U.S. Patent No. 5,517,313) or can be bound to polymeric material such as test paper for visual inspection. This latter technique would permit, for example, glucose measurement in a manner analogous to determining pH with a strip of litmus paper. The compounds described herein may also be utilized as simple reagents with standard benchtop analytical instrumentation such as spectrofluorometers or clinical analyzers as made by Shimadzu, Hitachi, Jasco, Beckman and others. These molecules would also provide analyte specific chemical/optical signal transduction for fiber optic-based sensors and analytical fluorometers as made by Ocean Optics (Dunedin, Florida), or Oriel Optics.
U.S. Patent 5,517,313, the disclosure of which is incorporated herein by reference, describes a fluorescence sensing device in which the compounds of the present invention can be used to determine the presence or concentration of glucose in a liquid medium. The sensing device comprises a layered array of a fluorescent indicator molecule-containing matrix (hereafter "fluorescent matrix"), a high-pass filter and a photodetector . In this device, a light source, preferably a light-emitting diode ("LED"), is located at least partially within the indicator material, or in a waveguide upon which the indicator matrix is disposed, such that incident light from the light source causes the indicator molecules to fluoresce. The high-pass filter allows emitted light to reach the photodetector, while filtering out scattered incident light from the light source. The fluorescence of the indicator molecules
employed in the device described in U.S. Patent 5,517,313 is modulated, e.g., attenuated or enhanced, by the local presence of glucose.
In the sensor described in U.S. Patent 5,517,313, the material which contains the indicator molecule is permeable to the analyte. Thus, the analyte can diffuse into the material from the surrounding test medium, thereby affecting the fluorescence emitted by the indicator compounds. The light source, indicator compound-containing material, high-pass filter and photodetector are configured such that at least a portion of the fluorescence emitted by the indicator compounds impacts the photodetector, generating an electrical signal which is indicative of the concentration of glucose in the surrounding medium.
In accordance with other possible embodiments for using the indicator compounds of the present invention, sensing devices also are described in U.S. Patent Nos. 5,910,661, 5,917,605 and 5,894,351, all incorporated herein by reference.
The compounds of the present invention can also be used in an implantable device, for example to continuously monitor blood glucose levels in vivo . Suitable devices are described in, for example, co- pending U.S. Patent Application Serial No. 09/383,148 filed August 26, 1999, as well as U.S. Patent Nos. 5,833,603, 6,002,954 and 6,011,984, all incorporated herein by reference.
The compounds of the present invention can be prepared by persons skilled in the art without an undue amount of experimentation using readily known reaction mechanisms and reagents, for example including reaction mechanisms which are consistent with the general procedures described below.
Example 1 Water soluble copolymer of anthracene derivative and MAPTAC
I . Synthesis of mono-boronate-anthracene indicator co-polymerized in water-soluble polymer:
A. 9- [3- (me hacryla ido)propylamino]methylanthracene To a suspension of N- (3-aminopropyl)methacrylamide hydrochloride salt (11.82g, 66.0 mmole, 3.0 equiv.) and DBMP (lOmg as inhibitor) in 250 mL CHC13 at 0°C was added dropwise DIEA (18.5 g, 25.0 mL, 144 mmole, 6.5 equiv.) over a 20 min period. The mixture was allowed to warm to 25 °C and then recooled to 0°C. To the cooled mixture was added dropwise a solution of 9-chloromethylanthracene (5.0 g, 22 mmole) in CHC13 (100 mL) over a 1 hour period. The mixture was subsequently stirred at 25°C for 1 hour, 50 °C for 12 hours and then 70°C for 2 hours. At this time, the mixture was washed with -4 x 60 mL portions of water, and the combined aqueous layers were extracted with CH2C12. The combined organic extracts were dried over anhydrous Na2S04, decanted and concentrated in vacuo . The crude material was purified by silica gel chromatography (flash silica gel, 2-5% CH30H/CH2C12) to yield 2.44 g (33%) of a solid product.
TLC: Merck silica gel 60 plates, Rf 0.39 with 90/10 CH2C12/CH30H, see with UV (254/366), ninhydrin stain. B. 9-[N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N-[3- (methacrylamido) propylamino]methylanthracene .
To a solution of 9- [3- (methacrylamido) propylamino] - methylanthracene (2.44 g, 7.34 mmole) and DBMP (10 mg as inhibitor) in 200 mL CHC13 at 0°C was added DIEA (2.85 g,
3.84 mL, 22.0 mmole, 3.0 equiv.) in portions over a 10 min period, followed by the dropwise addition of a solution of (2-bromomethylphenyl) boronic acid neopentyl ester (2.49 g, 8.81 mmole, 1.2 equiv.) over a 30 min period. The mixture was subsequently stirred at 25°C for 20 hours. At this time, the mixture was washed with water, and the combined aqueous layers were extracted with CH2C12. The combined organic extracts were dried over anhydrous Na2S04, decanted and concentrated in vacuo . The crude material was purified by silica gel chromatography (flash silica gel, 2-5% CH30H/CH2C12) to yield 2.50 g (76%) of a lightly yellow crystalline solid.
Mp: 72-73°C.
TLC: Merck silica gel 60 plates, • Rf 0.36 with 90/10 CH2C12/CH30H, see with UV (254/366), ninhydrin stain.
C. Water soluble copolymer of 9- [N- [2- (5 ,5-dimethyl- borinan-2-yl)benzyl] -N- [3- (methacrylamido)propylamino] - methylanthracene and MAPTAC (1:20 molar ratio) .
To a solution of 9- [N- [2- (5, 5-dimethylborinan-2-yl) - benzyl] -N- [3- (methacrylamido) propylamino] methylanthracene (0.0490 g, 0.105 mmole) and [3- (methacrylamido) propyl] - trimethylammonium chloride (MAPTAC, 50 wt % aqueous solution, 0.48 g, 0.90 mL, 2.1 mmole, 20 equiv.) in 1.5 mL ethylene glycol was added , 4 ' -azobis (cyanovaleric acid) (0.008 g, 0.03 mmole, 1.4 mole % of total monomer) . The solution was purged with argon gas for 5 minutes and then heated to 60°C in the dark for 18 hours. At this time, the viscous solution was cooled to 25°C, diluted with 5 mL water and dialyzed through a cellulose ■ acetate membrane (MWCO 3500) against 3 x 4 L of water.
The dialyzed material was concentrated to dryness to yield 0.339 g (68%) of a yellow glassy solid.
II . Modulation of Fluorescence With Glucose and Lactate The modulation of the fluorescence of the copolymer (which contains a single recognition element) prepared in this example by glucose and lactate was determined. Figure 1 shows the normalized fluorescence emission (I/Io @ 420 nm) of 0.5 mg/mL solutions of the copolymer (1:20 molar ratio) in PBS containing a) 0-20 mM glucose; b)
0-20 mM lactate. Spectra were recorded using a Shimadzu RF-5301 spectrafluorometer with excitation @365 nm; excitation slits at 1.5 nm; emission slits at 5 nm; ambient temperature. Error bars are standard deviation with duplicate values for each data point. The fluorescence of the copolymer was affected by the presence of glucose and lactate.
Example 2 Modulation of bis-boronate-indicator covalently attached to water-soluble polymer by glucose and potential physiological inter erences .
I. Synthesis of single-methacrylate monomer of bis-boronate-anthracene indicator
A. 9,10-bis[ [2- (2-hydroxyethoxy) ethylamino]methyl] anthracene.
To a solution of 2- (2-aminoethoxy) ethanol (31.4 g, 30.0 mL, 299 mmole, 20.9 equiv.) in 40 mL CHC13 at 23°C was added 9, 10-bis (chloromethyl) anthracene (3.94 g, 14.3 mmole) . The solution was stirred in the dark for 67 hours. At this time, added 100 mL CH2C12 and washed with 1 x 50 mL and 2 x 100 mL portions of NaHC03 (saturated aqueous solution) . The organic extract was dried over anhydrous Na2S04, filtered and concentrated to yield 4.67 g (79%) of a yellow powder. Product (-85 % pure by RP-HPLC) was carried on as is.
HPLC conditions: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2 mL/min, 370 n detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min,
• 80-100% B over 2 min, 100 %B 2 min, retention time 15.6 min.
B. 9, 10-bis [N- [2- (5,5-dimethylborinan-2-yl)benzyl] -N- [2- (2-hydroxyethoxy)ethylamino]methyl] anthracene.
A solution of 9, 10-bis [ [2- (2-hydroxyethoxy) - ethylamino]methyl] anthracene (4.02 g, 9.75 mmole), DIEA (12.6 g, 17.0 mL, 97.5 mmole, 10.0 equiv.) and (2-bromomethylphenyl) boronic acid neopentyl ester (13.7 g, 48 mmole, 4.9 equiv.) in 125 mL CHC13 at 23°C was
stirred in the dark for 46 hours. At this time, the reaction mixture was concentrated initially by rotary evaporation, then using a vacuum pump to remove the DIEA. The residue was purified by alumina column chromatography (150 g activated neutral alumina, 0-3% CH30H/CH2C12) to yield 5.67 g (70%) of a viscous oil which solidified upon standing. Product (-85 % pure by RP-HPLC) was carried on as is .
TLC: Merck basic alumina plates, Rf 0.33 with 95/5 CH2C12/CH30H, see with UV (254/366) .
HPLC conditions: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2 mL/min, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA) , gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 18.8 min.
C . 9- [N- [2- (5 ,5-dimethylborinan-2-yl)benzyl] -N- [2- (2-me hacroyloxyethoxy) ethylamino]methyl] -10- [N- [2- (5 , 5-djmethylborinan-2-yl) benzyl] -N- [2- (2-hydroxyethoxy) ethylamino] -methyl] anthracene . (Single- methacrylate monomer)
A solution of 9, 10-bis [N- [2- (5, 5-dimethyl- borinan-2-yl) benzyl] -N- [2- (2-hydroxyethoxy) ethylamino] - methyl] anthracene (0.298 g, 0.359 mmole), methacrylic acid (0.304 g, 0.300 mL, 3.53 mmole, 9.84 equiv.), DCC (0.965 g, 4.68 mmole, 13.0 equiv.) and N, N-dimethyl- aminopyridine (0.020 g, 0.16 mmole, 0.46 equiv.) in 15 mL CH2C12 at 23°C was stirred in the dark for 4 hours. At this time, the reaction mixture was filtered and concentrated by rotary evaporation. The residue was purified by alumina column chromatography (50 g activated neutral alumina, 0-4% CH30H/CH2C12) to yield 0.150 g (47%) of a yellow solid.
FAB MS: Calc=d for C52H66B2N209 [M]+ 885; Found [M + 1] + 886.
TLC: Merck basic alumina plates, Rf 0.45 with 95/5 CH2C12/CH30H, see with UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2 mL/min, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 21 min.
D. Water soluble copolymer of 9- [N- [2- (5 , 5-dimethyl- borinan-2-yl)benzyl] -N- [2- (2-methacroyloxyethoxy) ethyl- amino]methyl] -10- [N- [2- (5 ,5-dimethylborinan-2-yl)benzyl] - N- [2- (2-hydroxyethoxy) ethylamino] -methyl] nthracene and TMAMA (1:50 molar ratio).
To a solution of [2- (methacryloxy) ethyl] trimethyl- ammoniu chloride (TMAMA, 70 wt% aqueous solution, 0.344 g monomer, 1.66 mmole, 50 equiv.) in 0.600 mL water was
added a solution of 9- [N- [2- (5, 5-dimethylborinan-2-yl) - benzyl] -N- [2- (2-methacroyloxyethoxy) ethylamino]methyl] - 10- [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [2- (2- hydroxyethoxy) ethylamino]methyl] anthracene (0.0024 g, 0.0033 mmole) in 3.00 mL MeOH. To this mixture was added 4 , 4 ' -azobis (4-cyanovaleric acid) (0.0075 g, 0.027 mmole, 1.6 mole % of total monomer). The solution was filtered through a 0.45μ membrane filter, was purged with nitrogen gas and then heated in the dark at 55°C for 16 hours. At this time, the viscous solution was cooled to 25°C and concentrated in vacuo. The residue was diluted with 20 mL water and filtered through a 0.2μ membrane filter. The polymer solution was dialyzed through a cellulose acetate membrane (MWCO 3500) against 2 x 4 L of water. From the dialysis was obtained 38.5 mL of polymer solution. Concentration of a portion of this solution to dryness indicated 0.0075g polymer per 1.0 mL solution. Overall 0.289g (77%) yield of polymer.
II. Modulation of Fluorescence With Glucose, Lactate and Acetoacetate
The modulation of the fluorescence of the copolymer (which contains two recognition elements) prepared in this example by glucose, lactate and acetoacetate was determined. Figure 2 shows the normalized fluorescence emission (I/Io @ 428 nm) of a 1.5 mg/mL solution of anthracene bis boronate-TMAMA (1:50 mole ratio) copolymer in PBS containing a) 0-20 mM glucose; b) 0-20 mM lactate; c) 0-20 mM lithium acetoacetate. Spectra were recorded using a Shimadzu RF-5301 spectrafluorometer with excitation @365 nm; excitation slits at 1.5 nm; emission slits at 1.5 nm; ambient temperature. The fluorescence of the copolymer was affected by the presence of glucose, but not by the presence of lactate or acetoacetate.
Example 3 Effect of lactate in solution on the dose response effect of glucose on the fluorescence of bis-boronate-anthracene indicator
A. 9 , 10-bis [ [2- (tert-butoxycarbonyl) ethylamino]methyl] - anthracene.
A solution of β-alanine tert-butyl ester hydrochloride (3.06 g, 16.8 mmole, 5.09 equiv.), DIEA (4.27 g, 5.75 mL, 33.0 mmole, 10.00 equiv.) and 9, 10- bis (chloromethyl) anthracene (0.910 g, 3.31 mmole) in 75 mL CHC13 at 23 °C was stirred in the dark for 93 hours. At this time, the solution was filtered and washed with 1 x 40 mL and 2 x 60 mL portions of NaHC03 (saturated aqueous solution) . The organic extract was dried over anhydrous Na2S04, filtered and concentrated to yield a crude yellow solid. The residue was purified by silica gel column chromatography (30 g gravity grade gel, 0-3% CH30H/CH2C12) to yield 1.06 g (65%) of a viscous yellow-orange. Product was carried on as is.
TLC: Merck silica gel 60 plates, Rf 0.33 with 95/5 CH2C12/CH30H, see with UV (254/366) .
B. 9, 10-bis [N- [2- (5,5-dimethylborinan-2-yl)benzyl] -N- [2- (tert-butoxycarbonyl) ethylamino]methyl] anthracene.
A solution of 9, 10-bis [ [2- (tert-butoxycarbonyl) - ethylamino]methyl] anthracene (1.60 g, 3.25 mmole), DIEA (4.45 g, 6.00 mL, 34.4 mmole, 10.6 equiv.) and (2- bromomethylphenyl) boronic acid neopentyl ester (4.80 g, 17.0 mmole, 5.'22 equiv.) in 30 mL CHC13 at 23°C was stirred in the dark for 4.5 days. At this time, 45 mL CHC13 were added to the mixture and the mixture was washed with 2 x 25 mL portions of NaHC03 (saturated aqueous solution) . The organic extract was dried over anhydrous Na2S04, filtered and concentrated to yield crude reddish oil. The residue was purified by alumina column chromatography (100 g activated neutral alumina, 0-3% CH30H/CH2C12) to yield ~ 3.5 g of an orange solid. The product was dissolved, followed by the formation of a white precipitate (DIEA-HBr salt) . The solution was filtered and the filtrate concentrated to yield 2.72 g (93%) of an orange solid. Product (>80 % pure by RP- HPLC) was carried on as is.
TLC: Merck basic alumina plates, Rf 0.66 with 95/5 CH2C12/CH30H, see with UV (254/366) .
HPLC conditions: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2 mL/min, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1%
HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80- 100% B over 2 min, 100% B 2 min, retention time 23.9 min.
C . 9 , 10-bis [N- (2-boronobenzyl) -N- [2- (carboxyethyl) amino] -methyl] anthracene .
A solution of 9, 10-bis [N- [2- (5, 5-dimethylborinan-2- yl) benzyl] -N- [2- (tert-butoxycarbonyl) ethylamino]methyl] - anthracene (0.556 g, 0.620 mmole) in 5 mL 20% TFA/CH2C12 at 23°C was stirred in the dark for 25 hours. At this time, the reaction mixture was concentrated under a stream of N2 gas. The residue was triturated with 3 x 10 mL portions of ether. The residual solid was dried in vacuo to yield 0.351g (87%) of a fluffy yellow powder.
FAB MS: Glyβerol matrix; Calc=d for C42H46B2N20ιO (bis glycerol adduct) [M]+ 760; Found [M]+ 760.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.025 mL injection, 0.75 mL/min, 1.5 mL injection loop, 360 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10- 80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 16.7 min.
D . Modulation of Fluorescence With Glucose and Lactate
The modulation of the fluorescence of the indicator compound (which contains two recognition elements)
prepared in this example by glucose and lactate was determined. Figure 3 shows the fluorescence (at 428 nm) of 75 μM solutions of bis carboxylate bis-boronate- anthracene indicator in PBS containing a) 0-10 mM glucose, 0 mM lactate; b) 0-10 mM glucose, 2 mM lactate; c) 0-10 mM glucose, 5 mM lactate. Spectra were recorded using a Shimadzu RF-5301 spectrafluorometer with excitation @365 nm; excitation slits at 1.5 nm; emission slits at 1.5 nm; ambient temperature. All points measured in triplicate, with ±1 SD error bars included. The presence of lactate did not substantially affect the fluorescence modulation of the indicator by glucose.
Example 4 Selectivity of Bis-Boronate Glucose Indicator for Glucose vs . Lactate and Acetoacetate When Indicator Covalently Immobilized in the Hydrogel
Preparation of Dual-Methacrylamide Monomer
A. 9, 10-bis [3- (methacrylamido) propylamino] - methylanthracene . A suspension of 9, 10-bis (chloromethyl) anthracene
(1.5 g, 5.45 mmole), DIEA (28.17 g, 38.00 mL, 218 mmole, 40 equiv.), N- (3-aminopropyl)methacrylamide hydrochloride salt (9.76 g, 54.5 mmole, 10.0 equiv.), and ~ 5 mg of BHT
in 200 mL CHC13 at 23°C was stirred in the dark for 4 days at 40°C. At this time, the temperature was increased to 45 °C and the mixture was stirred for 3 days longer. At this time, a precipitate had formed. The mixture was filtered, and the solid product dissolved in the minimum amount of CH2C12. A yellow crystalline solid, the bis hydrochloride salt of the desired product, formed overnight (3.15 g, quantitative).
TLC: Merck basic alumina plates, Rf 0.31 with 90/10 CH2C12/CH30H, see with UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.100 mL injection, 0.75 mL/min, 360 nm detection, A = water (0.1% HFBA) and B = MeCN
(0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 15.0 min.
B . 9 , 10-bis [N- [2- (5 , 5-dimethylborinan-2-yl) benzyl] -N-
[3- (methacrylamido) ropylamino] ethylanthracene . (Dual- methacrylamide monomer)
A solution of 9, 10-bis [3- (methacrylamido) - propylamino] methylanthracene (0.0.650 g, 1.34 mmole of
the free amine), DIEA (0.612 g, 0.825 mL, 4.74 mmole, 3.55 equiv.), (2-bromomethylphenyl) boronic acid neopentyl ester (1.34 g, 4.74 mmole, 3.55 equiv.) and BHT (5 mg as inhibitor) in 20 mL CHC13 at 23 °C was stirred in the dark for 5 days. At this time, the reaction mixture was concentrated in va cuo and the residue was purified by alumina chromatography (200 g activated neutral alumina, 0-2% CH30H/CH2C12) to yield 0.465 g (39%) of a very viscous yellow oil.
TLC: Merck basic alumina plates, Rf 0.59 with 90/10 CH2C12/CH30H, see with UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 360 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18- min, 80-100% B over 2 min, 100% B 2 min, retention time 16.9 min.
C. Preparation of N,N-dimethylacrylamide hydrogel with glucose indicator:
A solution of N, N-dimethylacrylamide (40% wt . ) and N,N=-methylenebisacrylamide (0.8% wt . ) in ethylene glycol was prepared. 9, 10-bis [N- [2- (5, 5-dimethylborinan-2-yl) - benzyl] -N- [3- (methacrylamido) propylamino] methylanthracene (17.8 mg, 2xl0~5 mole) and 40 μL of aqueous ammonium persulfate (5% wt) were combined with 1 mL of ethylene glycol monomer solution. The resulting solution was placed in a glove box purged with nitrogen. An aqueous solution of N, N,N=,N=-tetramethylethylenediamine (80 μL, 5% wt . ) was added to the monomer formulation to accelerate polymerization. The resulting formulation was poured in a mold constructed from microscope slides and
100 micron stainless steel spacer. After being kept for 8 hours in nitrogen atmosphere the mold was placed in phosphate buffered saline (PBS) (10 M PBS, pH=7.4), the microscope slides were separated, and the hydrogel was removed. The hydrogel was washed with 100 mL of PBS containing 1 mM lauryl sulfate sodium salt and 1 mM EDTA sodium salt for 3 days, the solution being changed every day, followed by washing with DMF/PBS (10/90 by vol., 3 x 100 mL) , and finally with PBS (pH=7.4, 3 x 100 mL) . The resulting hydrogel polymer was stored in PBS (10 mM PBS, pH=7.4) containing 0.2% wt . sodium azide and 1 mM EDTA sodium salt.
II. Modulation of Fluorescence With Glucose, Lactate and Acetoacetate
The modulation of the .fluorescence of the indicator compound (which contains two recognition elements) prepared in this example by glucose, lactate and acetoacetate was determined. Figure 4 shows the normalized fluorescence emission (I/Io @ 427 nm) of a hydrogel containing the glucose recognition molecule of this example in 10 mM PBS, pH 7.4 containing 0.2% NaN3 and 1 mM EDTA containing various amounts of sodium-L-lactate, lithium acetoacetate or α-D-glucose. Data were recorded using a Shimadzu RF-5301 spectrofluorometer with excitation @365 nm (slit = 3 nm) and emission at 427 nm (slit = 3 nm) at low sensitivity at 37°C using a temperature controlled sample holder. The cuvettes containing 3 mL of the desired solution were equilibrated at 37 °C for 15 minutes before measurement. Each hydrogel sample was measured in four independent samples. Error bars are standard deviation with quadruplicate values for each data point. The hydrogels containing a glucose recognition molecule were prepared as previously described. The hydrogels were mounted on glass slides
and covered with polyester mesh in PMMA cuvettes at 45D to the incident light. Solutions of 1, 5, 10 and 20 mM sodium L-lactate [Aldrich] , 5, 10 and 20 mM lithium acetoacetate [Aldrich], and 1, 2, 4, 5, 10, and 20 mM α-D-glucose were prepared in 10 mM PBS, pH 7.4 containing 0.2% NaN3 and 1 mM EDTA. The fluorescence of the copolymer was affected by the presence of glucose, but not by the presence of lactate or acetoacetate.
Example 5
Glucose selectivity vs . lactate using bis-boronate recognition and proximity quenching signal generation
A. N- (2 , 2-diethoxyethyl) -4-bromo-l , 8-naphthalimide . A suspension of 4-bromo-l, 8-naphthalic anhydride
(10.0 g, 36.1 mmol) and aminoacetaldehyde diethyl acetal (4.81 g, 5.26 mL,' 36.1 mmol, 1 equiv.) in 45 mL EtOH was stirred at 45°C for 3 days. At this time, the resulting suspension was filtered, washing with EtOH and the residue was dried to yield 13.3 g (94%) of a light brown solid product.
TLC: Merck silica gel 60 plates plates, Rf 0.17 with 98/2 CH2C12/CH30H, see with UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 1.5 mL injection loop, 360 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 24.2 min.
B . N- (2 , 2-diethoxyethyl) -4-butylamino-l , 8-naphthalimide .
A solution of N- (2, 2-diethoxyethyl) -4-bromo-l, 8-
naphthali ide (0.797 g, 2.03 mmol) and n-butylamine (1.48 g, 2.00 mL, 20.2 mmol, 9.96 equiv.) in 8 mL NMP was heated at 45°C for 66 hours. At this time, the resulting suspension was allowed to cool to 25°C, followed by filtration. The residue was dissolved with 50 mL ether and extracted 3 x 50 mL water. The organic extract was dried over anhydrous Na2S04, filtered and concentrated to yield a crude yellow powder. The crude material was purified by silica gel chromatography (25 g gravity grade gel, 0-1% CH30H/CH2C12) to yield 0.639 g (82%) of a yellow powder.
TLC: Merck silica gel 60 plates, Rf 0.71 with 95/5 CH2C12/CH30H, see with UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 1.5 mL injection loop, 450 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 23.5 min.
C . N- (2-oxoethyl) -4-butylamino-l , 8-naphthalimide .
A solution of N- (2, 2-diethoxyethyl) -4-butylamino- 1, 8-naphthalimide (0.622 g, 1.62 mmol) and p-toluene- sulfonic acid mono hydrate (0.010 g, 0.053 mmol, 0.032 equiv.) in 25 mL acetone was stirred at 25°C for 18 hours. At this time, the solution was concentrated and the residue purified by silica gel chromatography (25 g gravity grade gel, 0-1% CH30H/CH2C12) to yield 0.470 g (94%) of an orange solid.
TLC: Merck silica gel 60 plates, Rf 0.61 with 95/5 CH2C12/CH30H, see with UV (254/366) .
xti NMR (400 MHZ, CDC13) ; δ 1.03 (t, 3H, J = 7.3 Hz), 1.53 (m, 2H) , 1.78 (m, 2H) , 3.38 (t, 2H, J = 7.2 Hz) , 5.02 (s, 2H), 6.64 (d, IH, J = 8.6 Hz), 7.52 (dd, IH, J = 7.4, 8.3 Hz), 8.08 (dd, IH, J = 1 Hz, 8.5 Hz), 8.38 (d, IH, J = 8.3 Hz), 8.46 (dd, 1 H, J = 1.0, 7.3 Hz), 9.75 (s, IH) .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 1.5 mL injection loop, 450 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min,
10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 19.6 min.
D . N- (4-dimethylaminobenzyl) -1 , 6-diaminohexane . A suspension of 4-dimethylaminobenzaldehyde (1.00 g, 6.70 mmol), Na2S0 (6.70 g, 47.2 mmol, 7.04 equiv.) and 1, 6-diaminohexane (3.89 g, 33.5 mmol, 5.00 equiv.) in 20 mL anhydrous EtOH was stirred in the dark at 25 CC under an atmosphere of nitrogen gas for 18 hours. At this time, the solution was filtered and NaBH4 (1.73 g, 45.8 mmol, 6.84 equiv.) was added to the filtrate. The suspension was stirred at 25°C for 5 hours. At this time, the reaction mixture was concentrated and the residue dissolved in 50 mL water and extracted 3 x 50 mL ether. The combined organic extracts were washed 2 x 50 mL water. The combined aqueous extracts were extracted 2 x 50 mL ether. The combined organic extracts were dried over Na2S04, filtered and concentrated to yield 1.35 g (81%) of a viscous oil.
TLC: Merck silica gel 60 plates plates, Rf 0.58 with 80/15/5 CH2Cl2/CH3OH/iPrNH2, see with ninhydrin stain, UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 1.5 mL injection loop, 280 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 13.3 min.
E . N-2- [6-N (N-4-dimethylaminobenzyl) aminohexyl] amino- ethyl) -4-butylamino-l , 8-naphthalimide . To a suspension of N- (2-oxoethyl) -4-butylamino-l, 8- naphthalimide (0.346 g, 1.11 mmol) in 25 mL anhydrous MeOH was added a solution of N- (4-dimethylamino- benzyl) -1, 6-diaminohexane (0.554 g, 2.22 mmol, 2.00 equiv.) and acetic acid (0.067 g, 1.1 mmol, 1.0 equiv.) in 20 mL anhydrous MeOH. To this mixture was added a solution of NaCNBH3 (0.070 g, 1.1 mmol, 1.0 equiv.) in 5 mL anhydrous MeOH. The reaction mixture was stirred at 25 °C for 15 hours. At this time, the MeOH was removed by rotary evaporation and the residue was dissolved in 30 mL water. The solution was adjusted to pH 2 with 1 N HCl and then stirred for 1 hour at 25°C. At this time, the solution was adjusted to pH 12 with 1 N NaOH and subsequently extracted 3 x 50 mL CH2C12. The combined organic extracts were washed 3 x 50 mL water, dried over anhydrous Na2S0, filtered and concentrated to yield a crude brown oil. The crude material was purified by silica gel chromatography (35 g flash grade gel, 0-50% CH30H/CH2C12, then 45/50/5 CH3OH/CH2Cl2/iPrNH2) to yield 0.190 g (32%) of diamine product.
FAB MS : Calc=d for C33H45N502 [M] + 544 ; Found [M] + 544 .
TLC : Merck silica gel 60 plates , Rf 0 . 42 with 80/20 CH2C12/CH30H, see with ninhydrin stain and UV ( 254 /366 )
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 1.5 mL injection loop, 450 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 17.6 min.
F . N-2- [6-N- (N-4-dimethylaminobenzyl) -6-N- [2- (5 , 5- dimethylborinan-2-yl)benzyl] aminohexyl] - [2- (5 , 5-dimethyl- borinan-2-yl) benzyl] aminoethyl-4-butylamino-l , 8- naphthalimide .
To a solution of N-2- [ 6-N- (N-4-dimethylaminobenzyl) - aminohexyl] aminoethyl) -4-butylamino-l, 8-naphthalimide (0.150 g, 0.276 mmole) and DIEA (0.355 g, 0.478 mL, 2.81 mmole, 10.0 equiv.) in 5 mL CHC13 was added a solution of (2-bromomethylphenyl) boronic acid neopentyl ester (0.390 g, 1.38 mmole, 5.00 equiv.) in 2 mL CHC13. The solution was subsequently stirred at 25°C for 27 hours. At this time, the mixture was concentrated and the residue was purified by alumina column chromatography (100 g activated neutral alumina, 0-5% CH30H/CH2C12) to yield 0.024 g (19%) of a viscous brown oil.
FAB MS (glycerol matrix): Calc' d for C53H67B2N508 [M] + 924 (bis glycerol adduct in place of bis neopentyl ester of boronic acids); Found [M]+ 924.
TLC: Merck neutral alumina plates, Rf 0.62 with 80/20 CH2C12/CH30H, see with UV (254/366') .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 1.5 mL injection loop, 450 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min,
10 -80% B over 18 min , 80- 100% B over 2 min, 100% B 2 min, re tention time 20 . 7 min .
G . N-2- [ 6-N- (N-4-dimethylaminobenzyl) -6-N- [2 - (borono) benzyl] aminohexyl] - [2- (borono) benzyl] amino- ethyl-4-butylamino-l , 8-naphthalimide (nBuF-hexa-Q bis-boronate) .
The free bis boronic acid product used in glucose studies results from dissolution of N-2- [ 6-N- (N-4- dimethyl-aminobenzyl ) -6-N- [2- ( 5 , 5-dimethylborinan-2 - yl ) benzyl ] amino-hexyl ] - [ 2- ( 5 , 5-dimethylborinan-2- yl ) benzyl ] aminoethyl-4 - butylamino-1 , 8 -naphthalimide in the MeOH/PBS buffer system .
H . Modulation of fluorescence with glucose and lactate . The modulation of the fluorescence of the indicator compound (which contains two recognition elements) prepared in this sample by glucose and lactate was determined. Figure 5 shows the normalized fluorescence emission (I/Io @ 535 nm) of 0.015 mM solutions of the indicator compund in 70/30 MeOH/PBS containing a) 0-20 mM glucose; b) 0-20 mM lactate. Spectra were recorded using a Shimadzu RF-5301 spectrafluorometer with excitation @ 450 nm; excitation slits at 1.5 nm; emission slits at 1.5 nm; ambient temperature. Error bars are standard deviation with triplicate values for each data point. The fluorescence of the indicator was affected by the presence of glucose, but not substantially affected by the presence of lactate.
Example 6 Effect of glucose or lactate on acrylamide gel containing N- [3- (methacrylamido)propyl] -3, 4-dihydroxy-9 , 10-dioxo-2- anthracenesulfonamide (Alizarin Red S monomer) and α , α ' -bis [N- [2- (5 , 5-dimethylborinan-2-yl)benzyl] -N- [3-
(methacrylamido)propylamino] -1,4-xylene (bis boronic acid monomer) :
A. 3 , 4-Dihydroxy-9 , 10-dioxo-2-anthracenesul onyl chloride:
3, 4-dihydroxy-9, 10-dioxo-2-anthracenesulfonic acid sodium salt (1.4 g, 3.9 mmoles) was combined with 30 mL of chlorosulfonic acid and heated to 90°C for 5 hours, after which the solution was cooled to 0°C and poured into 100 g of ice. After the ice melted the solution was extracted with CH2C12 (3 x 100 mL) , methylene chloride extracts were combined, dried with Na2S0 and evaporated to produce 0.87 g of solid (Yield 66%).
B. N- [3- (methacrylamido)propyl] -3, 4-dihydroxy-9, 10- dioxo-2-anthracenesulfonamide :
3, 4-dihydroxy-9, 10-dioxo-2-anthracenesulfonyl chloride (96 mg, 0.28 mmoles) and N- (3-aminopropyl) methacrylamide hydrochloride (108 mg, 0.6 mmoles) were combined with 20 mL of CH2C12. To this suspension Et3N
(303 mg, 3 mmoles) was added. The mixture was stirred at room temperature for 24 hours, filtered, and solvent was evaporated. The resulting solid was subjected to column chomatography on Si02 (10 g) with CH2Cl2/MeOH (90/10) as an eluent. The product was obtained as a red solid (80 mg, 64% yield) .
FAB MS: Calculated for C2ιH2oN2θ7S M+ 445; Found M+ 445.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.100 mL injection, .0.75 mL/min, 2 L injection loop, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-ϊ00% B over 2 min, 100% B 2 min, retention time 17.67 min.
C. α,α' -bis [3- (methacrylamido)propylamino] -1,4-xylene.
A solution of N- (3-aminopropyl) methacrylamide hydrochloride salt (3.00 g, 16.8 mmole, 2.21 equiv.), DIEA (6.5 g, 8.8 mL, 50 mmole, 6.6 equiv.), terephthaldicarboxaldehyde (1.02 g, 7.60 mmole) and Na2S04 (10.7 g, 75.3 mmole, 9.91 equiv.) in 75 mL anhydrous MeOH was stirred in the dark at 25DC for 18 hours. At this time, more Na2S04 (10.7 g, 75.3 mmole, 9.91 equiv.) was added and stirring continued for 6 hours longer. At this time, the solution was filtered and NaBH4 (1.73 g, 45.7 mmole, 6.01 equiv.) was added to the filtrate in portions and subsequently stirred at 25°C for 21 hours. The suspension was filtered through Celite and the filtrate was concentrated. The residue was dissolved in 100 mL CH2C12 and washed 1 x 25 mL saturated aqueous NaHC03. The organic extract was dried over anhydrous Na2S04, filtered and concentrated to yield a viscous oil. The product was carried on as is.
HPLC: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2.00 mL/min, 260 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA) , gradient 10% B 2 min, 10-80% B over 18 min,
80-100% B over 2 min, 100% B 2 min, retention time 15.8 min.
D. o,oc=-bis [N- [2- (5, 5-dimethylborinan-2-yl)benzyl] - N- [3- (methacrylamido) propylamino] -1 , 4-xylene .
A solution of α, α=-bis [3- (methacrylamido) - propylamino] -1, 4-xylene (2.94 g, 7.61 mmole), DIEA (2.97 g, 4.00 mL, 23.0 mmoles, 3.02 equiv.), (2-bromomethyl- phenyl) boronic acid neopentyl ester (6.50 g, 23.0 mmole, 3.02 equiv.) and BHT (5 mg as inhibitor) in 75 mL CH2C12 at 25°C was stirred in the dark for 28 hours. At this time, the mixture was washed 1 x 25 mL saturated aqueous NaHC03. The organic extract was dried over anhydrous Na2S0 , filtered and concentrated. To the residue was added 200 mL ether and the suspension was stirred for 18 hours. The suspension was filtered and the residue dissolved in CH2C12, filtered and the filtrate concentrated. To the solid residue was added 150 mL ether and the suspension was stirred for 18 hours. At this time, the suspension was filtered yielding 1.98 g (33%) of a fluffy pink powder.
FAB MS: Calc=d for C46H64B2N406 [M]+ 790; Found [M + 1] + 791.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 280 nm detection, A = water (0.1% HFBA) and B = MeCN
(0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 13.4 min.
E. Preparation of acrylamide gel containing
N- [3- (methacrylamido) propyl] -3 , 4-dihydroxy-9 , 10-dioxo-2- anthracenesulfonamide (Alizarin Red S monomer) and α,σ' -bis[N- [2- (5, 5-dimethylborinan-2-yl)benzyl] -N- [3- (mβthacryla ido) propylamino] -1 , 4-xylene :
Ethylene glycol solution containing 30% wt . acrylamide and 0.8% wt . N, N ' -methylenebisacrylamide was prepared.
N- [3- (methacrylamido) propyl] -3, 4-dihydroxy-9, 10-dioxo-2-a nthracenesulfonamide (1.5 mg, 3.38 x 10"6 mole) and α,α'-bis [N- [2- (5, 5-dimethyl- borinan-2-yl) benzyl] -N- [3- (methacrylamido) propylamino] -1, 4-xylene (28 mg, 3.54 x 10"5 mole) were combined with 800 μL of ethylene glycol monomer solution and 40 μL of 5% wt . aqueous ammonium persulfate. This formulation was placed in a glove box purged with nitrogen along with a mold constructed from glass microscope slides and 100 micron stainless steel spacer. An aqueous solution of N,N,N ' ,N' -tetramethylethylenediamine (40 μL, 5% wt . ) was added to the monomer solution to accelerate polymerization and the final formulation was poured into a glass mold. The mold was left under nitrogen atmosphere for 16 hours, after which it was immersed in PBS (pH=7.4) and the glass slides were separated to afford a hydrogel polymer in a form of a thin film. The resulting hydrogel thin film was washed with 100 mL of phosphate buffered saline containing 1 mM lauryl sulfate sodium salt for 3 days, the solution being changed every day, followed by washing with MeOH/PBS (20/80 by vol., 3 x 100 mL), and finally with PBS (pH=7.4, 3 x 100 mL) . Hydrogel polymer was stored in PBS (10 mM PBS, pH=7. ) containing 0.2% wt. sodium azide and 1 mM EDTA sodium salt.
F. Modulation of Absorbance With Glucose and Lactate
The modulation of the absorbance of the indicator hydrogel (which contains two recognition elements) prepared in this example by glucose and lactate was determined. The acrylamide gel was mounted in PMMA cell in the same way as described in Example 4. Phosphate
buffered saline (PBS), pH=7.4 containing desired amount of glucose or sodium lactate was heated to 37 °C in a water bath and placed in the PMMA cell containing the gel after which the PMMA cell was allowed to equilibrate for 15 min at 37 °C. Absorbance measurement for each glucose or lactate concentration was conducted in triplicate. For each measurement, absorbance at 650 nm was used as a blank, A (650 nm) was subtracted from all values of A(450nm) and A(530 nm) . Figure 6 shows the absorbance spectra for acrylamide gel (30%) containing 4 mM Alizarin Red S monomer and 44 mM bis boronic acid monomer with and without glucose. Figure 7 shows the effect of glucose on absorbance of acrylamide gel (30%) containing 4 mM Alizarin Red S monomer and 44 mM bis boronic acid monomer. Figure 8 shows the effect of sodium lactate on absorbance of acrylamide gel (30%) containing 4 mM Alizarin. Red S monomer and 44 mM bis boronic acid monomer. The absorbance of the indicator was affected by the presence of glucose, but not substantially affected by the presence of lactate.
G. Modulation of Fluorescence With Glucose and Lactate
The modulation of the fluorescence of an acrylamide gel synthesized substantially in accordance with this
Example 6 (except that 1.9 mg of N- [3- (methacrylamido) - propyl] -3, 4-dihydroxy-9, 10-dioxo-2-anthracenesulfonamide and 35 mg of α, ' -bis [N- [2- (5, 5-dimethylborinan-2-yl) - benzyl] -N- [3- (methacrylamido) propylamino] -1, 4-xylene were used) was determined.
The experiment was conducted in a Shimadzu RF-5301 PC spectrofluorimeter equipped with a variable temperature attachment (excitation at 470 nm, slits 3/10 nm, high sensitivity) . The acrylamide gel was attached to a piece of a glass slide which was glued in a PMMA
fluorescence cell at a 45° angle. The cell was filled with 2.5 ml of PBS (pH=7.4) and heated to 37°C. Stock solutions of glucose (100 mM and 500 mM) in PBS (pH=7.4) were prepared and heated to 37°C in a water bath. An aliquot of heated glucose stock solution was added to the PMMA cell periodically while the fluorescence intensity at 550 nm was monitored as a function of time (1 measurement every 2 minutes) . Glucose concentration in the PMMA cell was measured using a YSI Model 2300 STAT plus glucose analyzer. The results, shown in Figure 9, show that the addition of glucose reduces the fluorescent intensity of the indicator hydrogel. The same effect is seen in Figure 10, which shows the effect of glucose on the fluorescence spectrum of the same type of gel. That effect is believed to occur because of the following considerations. The methacrylamide monomer of Alizarin Red S (reporter molecule) contains a vicinal diol functionality and monomer functionality (see structure below) . In aqueous solution and in organic solvents, the Alizarin Red S and bis-boronate recognition element monomers (see structure below) are capable of reversible reaction with each other to form a boronate ester. The boronate ester molecule formed in this reversible reaction is fluorescent, while the Alizarin Red S monomer by itself displays virtually no fluorescence emission in aqueous solution and in organic solvents, such as MeOH. Thus upon binding to the glucose recognition element, Alizarin Red S changes its optical properties, such as absorbance and quantum yield of fluorescence, for example.
Alizarin Red S with with monomer functionality
A solution of Alizarin Red S with monomer functionality and glucose recognition element with monomer functionality can be prepared together with a hydrogel monomer and a crosslinker. Copolymerization of this mixture produces a hydrogel material which is diffusable to various small and medium size molecules; thus it is capable of analyte detection and quantitation. An analyte, such as glucose for example, would diffuse inside the hydrogel matrix and displace the reporter molecule previously bound to the recognition element. This event causes a change in the optical properties of the hydrogel film since it now contains a greater number of reporter molecules unbound to the recognition element. The modulation of the fluorescence of the indicator compound (which contains two recognition elements) prepared in this example by glucose and lactate was also determined. The experiment was conducted in a Shimadzu RF-5301 PC spectrofluorimeter equipped with a variable temperature attachment (excitation at 470 nm, slits 5/10 nm, low sensitivity) . The acrylamide gel was attached to a piece of a glass slide which was glued in a PMMA fluorescence cell at a 45° angle. The cell was filled with 2.5 ml of PBS (pH=7.4) and heated to 37 °C in a water
bath. A stock solution of sodium lactate (100 mM) in PBS (pH=7.4) was prepared and heated to 37°C in a water bath. Stock solutions of glucose (100 mM and 500 mM) in PBS (pH=7.4) were prepared and heated tθ'37°C in a water bath. An aliquot of heated lactate stock solution was added to the PMMA cell periodically while the fluorescence intensity at 550 nm was monitored as a function of time (1 measurement every 2 minutes), until the lactate concentration reached 8 mM. Then, an aliquot of heated glucose stock solution was added to the PMMA cell periodically while the fluorescence intensity at 550 nm was monitored as a function of time (1 measurement every 2 minutes). Glucose concentration in the PMMA cell was measured using a YSI Model 2300 STAT plus glucose analyzer. The results, shown in Figure 11, show that the addition of lactate had no significant effect on the fluorescent intensity of the indicator hydrogel, and the subsequent addition of glucose reduced the fluorescent intensity of the indicator hydrogel.
Example 7
Single-methacrylamide monomer of bis-boronate-anthracene:
A. 9-chloromethyl-10- [ [2- (2-hydroxyethoxy) ethylamino] - methyl] anthracene hydrochloride salt.
To a suspension of 9, 10-bis (chloromethyl) anthracene (5.18 g, 18.8 mmole, 3.99 equiv.) in 200 mL of NMP was
added 2- (2-aminoethoxy) ethanol (0.495 g, 0.475 mL, 4.71 mmole) . The mixture was stirred in the dark for 17 hours. At this time, the reaction mixture was concentrated to ~ 50 mL under vacuum at 50 °C. The residue was purified by silica gel chromatography (150 g gravity grade silica gel, 0-10% CH3OH/CH2Cl2) to yield 0.425 g (24%) of a yellow/orange solid.
TLC: Merck silica gel 60 plates, Rf 0.72 with 70/30 CH2C12/CH30H, see with UV (254/366), ninhydrin stain.
HPLC: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2 mL/min, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 16.1 min.
B. 9-[ [2- (2-hydroxyethoxy) ethylamino]methyl] -10- [ [ (3- methacrylamido)propylamino]methyl] -anthracene .
To. a suspension of N- (3-aminopropyl) methacrylamide hydrochloride salt (3.08 g, 17.2 mmole, 4.2 equiv.), DIEA (5.19 g, 7.00 mL, 40.1 mmole, 9.8 equiv.) and ~ 3 mg of BHT in 125 mL CHC13 at 23 °C was added dropwise a solution of 9-chloromethyl-10- [ [2- (2-hydroxyethoxy) ethylamino] - methyl] anthracene hydrochloride salt (1.56 g, 4.10 mmole) in 25 mL of CHC13. The mixture was subsequently stirred in the dark for 92 hours. At this time, the reaction mixture was filtered and washed with 2 x 40 mL of NaHC03
(saturated aqueous solution) . The organic extract was dried over anhydrous Na2S04, filtered and concentrated to yield a sticky orange solid which was purified by alumina chromatography (50 g activated neutral alumina, 0-5% CH30H/CH2C12) to yield 0.364 g (20%) of an orange solid.
TLC: Merck silica gel 60 plates, Rf 0.16 with 70/30 CH2C12/CH30H, see with UV (254/366), ninhydrin stain
HPLC: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2 mL/min, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 16.85 min.
C . 9- [N- [2- (5 , 5-dimethylborinan-2-yl) benzyl] -N- [3- (methacrylamido) propylamino]methyl] -10- [N- [2- (5,5- diπtethylborinan-2-yl) benzyl] -N- [2- (2-hydroxyethoxy) - ethylamino]methyl] anthracene. (Single-methacrylamide monomer)
A solution of 9- [ [2- (2-hydroxyethoxy) ethylamino] - methyl] -10- [ [ (3-methacrylamido) propylamino] methyl] - anthracene (0.343 g, 0.763 mmole), DIEA' (0.965 g, 1.30 mL, 9.8 equiv.) and (2-bromomethylphenyl) boronic acid
neopentyl ester (1.09 g, 3.85 mmole, 5.0 equiv.) in 20 mL CHC13 at 23°C was stirred in the dark for 25 hours. At this time, the reaction mixture was concentrated initially by rotary evaporation, then using a vacuum pump to remove DIEA. The residue was purified by alumina column chromatography (40 g activated neutral alumina, 0- 10% CH30H/CH2C12) to yield 0.299 g (46%) of a yellow orange solid. This compound may be co-polymerized with a suitable monomer as described previously, deprotected, and used to detect glucose.
FAB MS: Calc=d for C51H65B2N307 [M]+ 854; Found [M + 1] + 855.
TLC: Merck basic alumina plates, Rf 0.35 with 95/5 CH2C12/CH30H, see with UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Vydac 201TP 10 x 250 mm column, 0.100 mL injection, 2 mL/min, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient
10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 19.7 min.
Example 8 Dual-methacrylate monomer of bis-boronate-anthracene
A. 9, 10-bis [N- [2- (5 ,5-dimethylborinan-2-yl) benzyl] -N- [2- (2-methacroyloxyethoxy) ethylamino]methyl] anthracene .
A solution of 9, 10-bis [N- [2- (5, 5-dimethylborinan-2- yl ) benzyl] -N- [2- (2-hydroxyethoxy) ethylamino]methyl] - anthracene (0.100 g, 0.120 mmole; see Example 2), methacrylic acid (0.112 g, 0.110 mL, 1.30 mmole, 10.8 equiv.), DCC (0.316 g, 1.53 mmole, 12.8 equiv.) and N,N- dimethylamino-pyridine (0.014 g, 0.11 mmole, 0.92 equiv.) in 5 mL CH2C12 was stirred at 0°C for 1 hour, then 23°C for 22 hours. At this time, the reaction mixture was filtered and concentrated by rotary evaporation. The residue was purified by alumina column chromatography (30 g activated neutral alumina, 0-2% CH30H/CH2C12) to yield 0.030 g (26%) of a yellow solid. This compound may be co-polymerized with a suitable monomer as described previously, deprotected, and used to detect glucose. FAB MS: Calc=d for C56H7oB2N2Oιo [M]+ 953; Found [M]+ 951 (weak molecular ion peak) .
TLC: Merck basic alumina plates, Rf 0.67 with 95/5 CH2C12/CH30H, see with UV (254/366) .
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.100 mL injection, 0.75 mL/min, 2 mL injection loop, 370 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10- 80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 19.6 min.
Example 9 Dual 5-aminopentyl bis-boronate-anthracene
A suspension of 9, 10-bis (chloromethyl) anthracene (0.28 g, 1 mmole), DIEA (7.0 mL, 40 mmole), mono-t- butoxycarbonyl 1, 5-diaminopentane (3.75 g, 10 mmole), and 50 ml of CHC13 was stirred in the dark for 2 days at 45°C. The solution was washed with saturated H20/NaHC03, the organic phase was dried (Na2S04) , and the solvent was evaporated. The residue was purified by alumina chromatography (40 g activated neutral alumina, 95/5 % vol. CH2Cl2/MeOH) to yield 0.55 g of viscous oil. This material was used as is for the next step.
B. 9, 10-bis [N- [2- (5 ,5-dimethylborinan-2-yl)benzyl] -N- [5- (t-BOC) -aminopentylamino]methyl] anthracene .
A solution of 9, 10-bis [ [5- (t-BOC) -aminopentylamino] - methyl] anthracene (0.3 g, 0.49 mmole), DIEA (0.35 mL, 2 mmole), and (2-bromomethylphenyl) boronic acid neopentyl ester (0.566 g, 2.0 mmole) in 20 mL CH2C12 was stirred in the dark for 2 days at 25°C. At this time, the reaction mixture was concentrated in vacuo and the residue was purified by alumina chromatography (60 g of activated neutral alumina, 98/2 % vol. CH2Cl2/MeOH) to yield 0.401 g of yellow oil. This material was used as is for the next step.
C . 9 , 10-bis [N- (2-boronobenzyl) -N- [5-aminopentylamino] methyl] anthracene trifluoroacetic acid salt.
9, 10-bis [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [5- (t-BOC) -aminopentylamino]methyl] anthracene (0.4 g, 0.39 mmole) was dissolved in 20 ml of CH2C12/TFA (80/20 % vol.). The solution was stirred for 12 hours, the solvent was evaporated, and the residue was washed with 10 ml of ether. A total of 373 mg of solid was obtained (72% yield) . Product was -80% pure by RP-HPLC. This compound may be co-polymerized with a suitable monomer as described previously, deprotected, and used to detect glucose.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.050 mL injection, 0.75 mL/min, 360 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 16.0 min.
Example 10
A. N-2- (tert-butoxycarbonyl) aminoethyl-4- bromonaphthalene-1 , 8-dicarboximide :
N-t-Boc-ethylenediamine (Fluka, 1.6 g, 10 mmole) and 4-bromo-l, 8-naphthalic anhydride (Aldrich, 2.77 g, 10 mmole) were combined with 60 ml of anhydrous ethanol, the
suspension was stirred at 60°C for 20 hours, cooled to room temperature, and filtered. The obtained solid was washed with 30 ml of cold EtOH and dried under vacuum. Yield 3.84 g (91%). NMR (CDC13) : 1.28 (9H, s); 3.52 (2H, t) ; 4.35 (2H, t) ; 4.92 (IH, s);7.84 (IH, t) ; 8.04 (IH, d) ; 8.42 (IH, d) ; 8.58 (IH, d) ; 8.67 (IH, d) .
B . N-2- (tert-butoxycarbonyl) aminoethyl-4- (N' - methylaminoethylamino) naphthalene-1 ,8-dicarboximide:
N-Methylethylenediamine (1.48 g, 20 mmole) was combined with 2 ml of l-methyl-2-pyrrolidinone (NMP) followed by addition of N-2- (tert- butoxycarbonyl) aminoethyl-4-bromonaphthalene-l, 8- dicarboximide (0.35 g, 0.845 mmole). The resulting solution was stirred at 45°C for 40 hours after which NMP and N-methylethylenediamine were evaporated under vacuum.
The obtained residue was subjected to column chromatography (20 g of silica gel, initially CH2Cl2/MeOH (90/10), then CH2Cl2/MeOH/Et3N (75/20/5)). A yellow solid was obtained (0.311 g, 89 % yield) . Purity was checked by RP-HPLC.
Methylene chloride solution containing 20% vol. TFA and 5% vol. triisopropyl silane was added to the resulting orange residue. The resulting solution was stirred at room temperature for 10 hours, after which the solvent was evaporated and the residue triturated with ether to yield a yellow solid. The solid was filtered and dried in vacuum (yield 580 mg) . Purity of the material was checked by RP-HPLC. The solid was used as is in the next step.
D . N- (3-Borono-5-nitrobenzamido) ethyl-4- (N' - aminoethylene-N' ' - [2 - (borono) benzylJmethylamino) naphthalene-1 , 8- dicarboximide :
N-aminoethyl-4- (N' -aminoethylene-N' ' - [2- (borono) benzyl]methylamino) naphthalene-1, 8- dicarboximide trifluoroacetic acid salt (0.225 g, 0.4 mmole), 3-carboxy-5-nitrophenylboronic acid (0.085 g, 0.4 mmole), diphenylphosphoryl azide (0.13 ml, 0.6 mmole), and 2 ml of anhydrous DMF were combined. N,N- diisopropyl-N-ethyl amine (0.7 ml, 4 mmole) was added and the solution was stirred for 20 hours. Ether (10 ml) was added to the reaction mixture and the insoluble residue was separated and sonicated with 5 ml of CH2C12 to yield an orange solid which was filtered and dried under vacuum (38 mg, 15% yield) . Purity of the solid was checked by RP-HPLC. NMR (dmso-d6/D20, 90/10): δ 2.32 (3H, s) ; 2.82 (2H, t); 3.58 (2H, t) ; 3.65 (2H, t), 3.70 (2H, s); 6.65 (IH, d) ; 7.0-7.3 (4H, m) ; 7.68 (IH, t); 8.18 (IH, d) ; 8.42 (IH, d) ; 8.47 (IH, d) ; 8.1-8.35 (3H, m) .
E. Test of N- (3-borono-5-nitrobenzamido) ethyl-4- (N' - aminoethylene-N' ' -
[2- (borono) benzyl]methylamino) naphthalene-1 ,8- dicarboximide for interaction with glucose as monitored by fluorescence
This experiment was conducted in MeOH/phosphate buffered saline, (PBS, 10 mM, pH=7.4 ) . The concentration of N- (3-borono-5-nitrobenzamido) ethyl-4- (N' - aminoethylene-N''- [2-
(borono) benzyl] methylamino) naphthalene-1 , 8-dicarboximide in MeOH/PBS, (50/50 vol. %) was 15 M. The glucose
concentration was varied from 0 mM to 50 mM, and the L- sodium lactate concentration was varied from 0 mM to 7 mM . The experiment was conducted in a Shimadzu RF-5301 PC spectrofluorimeter: excitation wavelength was set at 430 nm, emission was monitored in the 480-650 nm range, slit width 3/1.5 nm, high sensitivity of PMT .
The results are shown in Figures 12 and 13, which show that the fluorescence of the indicator of this example was affected by the presence of glucose, but not by the presence of lactate.
Example 11
6- (Cyclohexanecarboxamido)hexylamine indicator monomer
A. 9- [N- [3- (methacrylamido)propylamino] ethyl] -10-N- [ (6-aminohexylamino)methyl] anthracene. To a solution of 3-aminopropylmethacrylamide (0.775 g, 5.45 mmol, 10.0 equiv.) and tert-butyl N- ( 6-aminohexyl) carbamate (1.18 g,
5.45 mmol, 10.0 equiv.) and several crystals of BHT in 200 mL CHC13 was added 9, 10-bis (chloromethyl) anthracene (0.150 g, 0.545 mmol). The reaction mixture was subsequently stirred in the dark at ambient temperature for 4 days. At this time, the CHC13 was evaporated and the residue was dissolved in 100 mL ether. The organic layer was extracted with 8 x 125 mL sat'd aqueous NaHC03 and 5 x 200 mL phosphate buffer (0.4 M, pH 7.0). The pH of the combined phosphate buffer washes was adjusted to pH 11 by addition of Na2C03 (sat'd aqueous solution), followed by extraction with 5 x 300 mL CH2C12. The combined organic layers were concentrated and the residue dissolved in 5 mL of a 20% solution of TFA in CH2C12. The mixture was stirred at ambient temperature for 2 hours . At this time, the reaction mixture was extracted with 4 x 10 mL sat'd aqueous NaHC03. The pH of the combined aqueous layers was adjusted to pH 11 by addition of Na2C03 (sat'd aqueous solution), followed by extraction with 4 x 75 mL CH2C12. The combined organic extracts were dried over anhydrous Na2S04, filtered and concentrated in vacuo to yield 0.068 g (27%) of product.
TLC: a) Merck Silica Gel 60 plates, Rf 0.16 with 70/30 CH2C12/CH30H, see with UV (254/366), prior to deprotection; Rf 0.27 with 85/14.5/0.5 CH2Cl2/CH3OH/iPrNH2, see with UV (254/366), final product .
HPLC: HP 1100 HPLC chromatograph, Waters 8 x 100 mm NovaPak HR C18 column, 0.100 mL injection, 0.75 mL/min, 0.400 mL injection loop, 360 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 15.5 min.
B. 9- [N- [3- (methacrylamido)propylamino]methyl] -10- [N- [6- (cyclohexanecarboxamido) exylamino]methyl] anthracene .
To a solution of 9-[N-[3- (methacrylamido) propylamino] methyl] -10-N- [6- aminohexylamino) methyl] anthracene (1.68 g, 3.63 mmol) and a few crystals of BHT in 20 mL CH2C12 at ambient temperature was added dropwise a solution of cyclohexanecarboxylic acid N-hydroxysuccinimide ester (0.845 g, 3.76 mmol, 1.03 equiv.) over a 1 hour period. The reaction was subsequently stirred in the dark at ambient temperature for 16 hours. At this time, the reaction mixture was concentrated in vacuo and the residue dissolved in 105 mL of a solution of 90/15 ether/ CH2C12. The organic layer was extracted with 4 x 225 mL phosphate buffer (0.4 M, pH 7.0). The pH of the combined phosphate buffer washes. was adjusted to pH 11 by addition of Na2C03 (sat'd aqueous solution), followed by extraction with 6 x 500 mL CH2C12. The combined organic layers were dried over anhydrous Na2S04, filtered and concentrated in va cuo to yield 1.2 g (60%) of product.
TLC: Merck Silica Gel 60 plates, Rf 0.30 with 85/14.5/0.5 CH2Cl2/CH3OH/iPrNH2, see with UV (254/366) HPLC: HP 1100 HPLC chromatograph, Waters 8 x 100 mm NovaPak HR C18 column, 0.100 mL injection, 0.75 mL/min, 0.400 mL injection loop, 360 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100%
B over 2 min, 100% B 2 min, retention time 17.4 min.
C. 9-[N-(2-boronobenzyl)-N-[3- (methacrylamido)propylamino]methyl] -10- [N- (2- boxonobenzyl) -N- [6- (cyclohexanecarboxamido) hexylamino] - methyl] anthracene. A solution of 9-[N-[3- (methacrylamido) propylamino] methyl] -10-[N-[6- (cyclohexanecarboxamido) hexylamino] methyl] -anthracene . (1.0 g , 1.8 mmol), DIEA (1.81 g, 2.44 mL, 14.0 mmol, 7.8 equiv. ) , 2-bromomethylphenylboronic acid pinacol ester (2.14 g, 7.20 mmol, 4.0 equiv.) and a few crystals of BHT in 30 mL CHC13 was stirred in the dark at ambient temperature for 60 hours. At this time, the reaction mixture was concentrated and the residue (9-[N-[2-
(4,4,5,5, -tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino] methyl] -10-[N-[2-(4, ,5,5, - tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [6- (cyclohexanecarboxamido) hexylamino]methyl] anthracene) suspended in 150 mL ether. The organic layer was washed with 4 x 50 mL phosphate buffer (0.4 M, pH 7.0). The organic layer was concentrated and the residue dissolved in ether in 200 mL 0.1 N aqueous HCl. The aqueous layer was washed with 3 x 50 mL 1:1; ether: ethyl acetate and the pH was adjusted to pH 11 by addition of Na2C03 (sat'd aqueous solution) , followed by extraction with 3 x 150 L CH2C12. The combined organic layers were dried over
anhydrous Na2S04, filtered and concentrated in vacuo to yield a red oily compound. The residue was dissolved in ether and concentrated in vacuo to yield 1.17 g (85%) of a yellow solid product. TLC: Merck Silica Gel 60 plates, Rf 0.59 with 80/20 CH2C12/CH30H, see with UV (254/366) HPLC: HP 1100 HPLC chromatograph, Waters 8 x 100 mm NovaPak HR C18 column, 0.100 mL injection, 0.75 mL/min, 0.400 mL injection loop, 360 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 19.6 min. ^ NMR (9:1 d6-acetone/D20) : δ 0.90 (m, 2H) , 1.03 (m, 2H) , 1.18-1.30 (m, 6H) , 1.35-1.48 (4H), 1.62 (m, IH, 0=C-CH(CH2)CH2) , 1.66-1.75 (m, 7H) , 1.77 (m, 2H, N-
CH2-CH2-CH2-N) , 2.52 (m, 2H, N-CH2-CH2-), 2.63 (m, 2H, N-CH2-CH2-), 2.98 (m, 4H, -CH2-NH-C=0) , 3.98 (s, 4H, benzene-CH2-N) , 4.57 (s, 2H, athracene-CH2-N) , 4.59 (s, 2H, athracene-CH2-N) , 5.20 (t, IH, J = 1.5 Hz, C=CH2) , 5.46 (s, IH, C=CH2) , 7.4-7.5 (m, 8H, Ar-H) ,
7.52 (m, 2H, Ar-H), 7.95 (m, 2H, Ar-H), 8.23 (m, 4H, Ar-H)
D. N,N-dimethylacrylamide hydrogel with 9- [N- (2- boronobenzyl) -N- [3- (methacrylamido) propylamino]methyl] - 10- [N- (2-boronobenzyl) -N- [6- (cyclohexanecarboxamido) hexylamino] methyl] anthracene. A solution of N, N-dimethylacrylamide (40% wt . ) and N,N'- methylenebisacrylamide (0.8% wt . ) in phosphate buffer, pH=7.4, 200 mM was prepared. 9- [N- (2-Boronobenzyl) -N- [3- (methacrylamido) propylamino]methyl] -10- [N- (2- boronobenzyl ) -N- [ 6- (cyclohexanecarboxamido) hexylamino] methyl] anthracene (18 mg, 2.15X10"5 mole) and 60 mg of fructose were combined with 2 mL of MeOH. This solution
was sonicated until all of the fructose dissolved and was subsequently evaporated to yield a solid. To this solid, 1 mL of phosphate buffer solution containing monomers was added. After sonication for 10 min this solution was filtered through a 0.2 μM PTFE membrane filter. Aqueous ammonium persulfate (20 μL, 5% wt . ) was combined with the formulation. The resulting solution was placed in glove box purged with nitrogen. An aqueous solution of N, N,N' ,N' -tetramethylethylenediamine (40 μL, 5% wt . ) was added to the monomer formulation to accelerate polymerization. The resulting formulation was poured into a mold constructed from glass microscope slides and a 100 μM stainless steel spacer. After being kept for 8 hours in a nitrogen atmosphere, the mold was placed in phosphate buffered saline (pH=7.4), the microscope slides were separated, and the hydrogel was removed. The hydrogel was washed 'with 100 mL of phosphate buffered saline (PBS) containing 1 mM lauryl sulfate sodium salt and 1 mM EDTA tetrasodium salt for 3 days, the solution being changed every day, followed by washing with
EtOH/PBS (20/80 by vol., 3 x 100 mL) , and finally with PBS (H=7.4, 3 x 100 mL) . The resulting hydrogel film was stored in PBS (pH=7.4) containing 0.02% wt . sodium azide and 1 mM EDTA tetrasodium salt.
E . Modulation of Fluorescence with Glucose .
The modulation of the fluorescence of the 6- (cyclohexanecarboxamido) hexylamine indicator/DMA hydrogel film prepared in this example by glucose and lactate was determined. Figure 14 shows the relative fluorescence emission (I @ 430 nm) of the hydrogel film in PBS (pH 7.4 containing 0.02% NaN3 and 1 mM EDTA) containing 0 to 20 mM α-D-glucose, 0 to 10 mM L-sodium lactate, and 0-20 mM α- D-glucose in the presence of 4 mM L-sodium lactate. The
hydrogel film (100 μm thickness, 8 mm diameter disk) was mounted in a PMMA cuvette at a 45° angle. All measurements were made at 37 °C in a Shimadzu RF-5301 spectrofluorometer with excitation at 370 nm (slit = 3 nm) and emission at 430 nm (slit = 3 nm) at low PMT sensitivity. Glucose and L-sodium lactate concentrations were checked using the YSI Model 2300 STAT plus glucose analyzer. Error bars are standard deviation with triplicate values for each data point. The fluorescence was affected by the presence of glucose, but not by the presence of lactate. Moreover, the presence of lactate (4 mM) had no significant effect on the 0-20 mM glucose calibration curve.
EXAMPLE 12
2- (carboxyethyl) amine indicator monomer
Chemical Name: 9- [N- (2-boronobenzyl) -N- [3-
(methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl) -N- [2-
(carboxyethyl) amino]methyl] anthracene (uncapped) Chemical Formula: C0H45B2N3O7 MW: 701.4
Physical appearance: faint yellow powder Solubility: PBS/methanol, methanol, ethanol,
chloroform, dichloromethane
Capped Indicator: 9- [N- [2- (4 , , 5, 5, -tetramethyl- 1,3, 2-dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino] methyl] -10- [N- [2- (4,4,5,5, -tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [2- (carboxyethyl) amino] methyl] anthracene.
I . Synthesis
A. 9- [N- [3- (methacrylamido) propylamino]methyl] -10- [N- [2- (tert-butoxycarbonyl) ethylamino] ethyl] nthracene. To a solution of 3-aminopropylmethacrylamide (12.9 g, 90.7 mmol, 4.99 equiv.), β-alanine tert-butyl ester (13.2 g, 90.9 mmol, 5.00 equiv.) and several crystals of BHT in 700 mL CHC13 was added 9, 10-bis (chloromethyl) anthracene (5.00 g, 18.2 mmol). The reaction mixture was subsequently stirred in the dark at 30 °C for 88 hours. At this time, the CHC1 was evaporated and the residue was dissolved in 500 mL ether. The solution was stirred for 1 hour at which time salts had precipitated from solution. The ether solution was filtered and subsequently extracted with 10 x 350 mL sat'd aqueous NaHC03. The ether layer was further extracted with 6 x 350 mL phosphate buffer (0.2 M, pH 6.5). The pH of the combined phosphate buffer washes was adjusted to pH 11-12 by addition of Na2C03 (sat'd aqueous solution), followed by extraction with 6 x 500 mL CH2C12. The combined organic
layers were dried over anhydrous Na2S04, filtered and concentrated in vacuo to yield an oily crude product. The crude product was purified by silica gel chromatography (50 g flash grade silica gel, 0-5% MeOH/CH2Cl2 step gradient) to yield 2.04 g of a sticky yellow solid (23%) .
TLC: Merck Silica Gel 60 plates, Rf 0.29 with 90/10 CH2C12/CH30H, see with UV (254/366) and ninhydrin stain.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.100 mL injection, 0.75 mL/min, 1.500 mL injection loop, 280 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100 % B 2 min, retention time 17.0 min.
B . 9- [N- [2- (4 , 4 , 5 , 5 , -tetramethyl-1 ,3,2- dioxaborolano)benzyl] -N- [3-
(methacryla ido)propylamino]methyl] -10- [N- [2-(4,4,5,5, tetramethyl-1, 3, 2-dioxaborolano)benzyl] -N- [2- (tert- butoxycarbonyl) ethylamino]methyl] anthracene. A solution of 9-[N-[3- (methacrylamido) propylamino]methyl] -10- [N- [2- (tert-
butoxycarbonyl) ethylamino] methyl] anthracene (1.5 g , 3.1 mmol), DIEA (3.16 g, 4.26 mL, 24.4 mmol, 7.9 equiv.), 2- bromomethylphenylboronic acid pinacol ester (3.64 g, 12.2 mmol, 3.9 equiv.) and a few crystals of BHT in 50 mL CHC13 was stirred in the dark at ambient temperature for 16 hours. At this time, the reaction mixture was concentrated and the residue suspended in 200 mL ether. The ether layer was extracted with 3 x 125 mL phosphate buffer (0.2 M, pH 7.0), dried over anhydrous Na2S04, filtered and concentrated in vacuo to yield a crude product. The residue was triturated with hexanes to yield 2.14 g (76%) of a white solid.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x- 100 mm NovaPak HR C18 column, 0.200 mL injection, 0.75 mL/min, 1.500 mL injection loop, 280 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 19.2 min.
C. 9-[N-(2-boronobenzyl)-N-[3- (methacrylamido)propylamino]methyl] -10- [N- (2- boronobenzyl) -N- [2- (carboxyethyl) amino]methyl] anthracene ,
A solution of 9-[N-[2-(4, 4, 5, 5, -tetramethyl-1, 3,2- dioxaborolano) benzyl] -N- [3-
(methacrylamido) propylamino] methyl] -10- [N- [2- (4,4,5,5,- tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [2- (tert- butoxycarbonyl) ethylamino] methyl] anthracene (0.294 g, 0.319 mmol) in 5 L of 20% TFA/CH2C12 was stirred in the dark at ambient temperature for 22 hours. At this time, the reaction mixture was concentrated and the residue triturated with ether. The residue was dissolved in 5 L 90:10 acetone/water and stirred for 2 hours. At this time, the reaction mixture was concentrated and the residue triturated with water and PBS (pH 7.4 containing 0.02% NaN3 and 1 mM EDTA) resulting in the recovery of 0.062 g (28%) of a light yellow solid.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.100 mL injection, 0.75 mL/min, 1.500 mL injection loop, 280 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100 % B 2 min, retention time 17.4 min.
FAB MS: Glycerol matrix; Calc'd for C6H53B2N30 (bis glycerol adduct) [M]+ 813; Found [M + 2]+ 815.
D. N,N-dimethylacrylamide hydrogel with 9-[N-(2- boronobenzyl) -N- [3- (methacrylamido) propylamino] ethyl] - 10- [N- (2-boronobenzyl) -N- [2-
(carboxyethyl) amino]methyl] anthracene. A solution of N,N-dimethylacrylamide (40% wt . ) and N,N'- methylenebisacrylamide (0.8% wt . ) in phosphate buffer, pH=7.4, 200 mM was prepared. 9- [N- (2-boronobenzyl) -N- [ 3-
(methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl) -N- [2- (carboxyethyl) amino]methyl] anthracene
(14 mg, 2.0 x 10"5 mole) and 60 mg of fructose were combined with 2 ml of MeOH. This solution was sonicated
until all fructose dissolved and evaporated to yield a solid. To this solid 1 ml of phosphate buffer solution containing monomers was added. After sonication for 10 minutes this solution was filtered through 0.2 μM PTFE filter. Aqueous ammonium persulfate (20 μL, 5% wt . ) was combined with the formulation. The resulting solution was placed in a glove box purged with nitrogen. An aqueous solution of N, N, N' , N' -tetrametylethylenediamine (40 μL, 5% wt . ) was added to the monomer formulation to accelerate polymerization. The resulted formulation was poured in a mold constructed from microscope slides and 100 μM stainless steel spacer. After being kept for 8 hours in nitrogen atmosphere the mold was placed in phosphate buffered saline (10 mM, pH=7.4 ) , the microscope slides were separated, and the hydrogel was removed. The hydrogel was washed with 100 ml of phosphate buffered saline (PBS) containing 1 mM lauryl sulfate sodium salt and 1 mM EDTA tetrasodium salt for 3 days, the solution being changed every day, followed by washing with EtOH/PBS (20/80 by vol., 3 x 100 ml), and finally with
PBS (pH=7.4, 3 x 100 ml). The resulting hydrogel film was stored in PBS (10 mM, pH=7.4) containing 0.02% wt . sodium azide and 1 mM EDTA tetrasodium salt.
II. Modulation of Fluorescence with Glucose.
The modulation of the fluorescence of the 2- (carboxyethyl) amine indicator/DMA hydrogel film prepared in this example by glucose and lactate was determined. Figure 15 shows the relative fluorescence emission (I @ 430 nm) of the hydrogel film in PBS (pH 7.4 containing 0.02% NaN3 and 1 mM EDTA) containing 0 to 20 mM α-D-glucose, 0 to 10 mM L- sodium lactate, and 0-20 mM glucose in the presence of 3 mM L-sodium lactate. The hydrogel film (100 μm thickness, 8 mm diameter disk) was mounted in a PMMA cuvette at a 45°
angle. All measurements were made at 37 °C in a Shimadzu RF- 5301 spectrofluorometer with excitation at 370 nm (slit = 3 nm) and emission at 430 nm (slit = 3 nm) at low PMT sensitivity. Glucose and L-sodium lactate concentrations were checked using the YSI Model 2300 STAT plus glucose analyzer. The data is plotted as the average of triplicate values for each data point. The fluorescence was affected by the presence of glucose, but not by the presence of lactate. Moreover, the presence of lactate (4 mM) had no significant effect on the 0-20 mM glucose calibration curve .
EXAMPLE 13 Fluorescent glucose indicator containing two detectable moieties :
Chemical Name: 9- [N- (2-boronobenzyl) -N- [ 3- (methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl) -N- [3- (N-6- (9- anthracenecarboxamido) hexylamino
carbonyl) ethylamino] methyl] anthracene (uncapped)
Chemical Formula: C73H87B2N507
MW: 1168
Physical appearance: faint yellow powder
Solubility: PBS/methanol, methanol, ethanol, chloroform, dichloromethane
Pinacol capped compound:
9- [N-[2- (4,4, 5, 5, -tetramethyl-1, 3, 2- dioxaborolano) benzyl] -N- [3-
(methacrylamido) propylamino] methyl] -10-[N-[2-(4,4,5,5, tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [3- (N-6- (9- anthracenecarboxamido) hexylamino carbonylethylaminomethyl] anthracene .
I . Synthesis
A. 9-Anthracenoyl Chloride: Anthracene-9- carboxylic acid (1.2 g, 5.4xl0~3 mole) was combined with 15 ml of thionyl chloride. The solution was refluxed for 2 hours followed by evaporation of the volatile components. The obtained solid was dried under high vacuum for 24 hours yielding 1.3 g of material (quantitative yield) . This material was used as is in the next step.
B . N- (6-Aminohexyl) -anthracene-9-carboxamide hydrochloric acid salt: 9-Anthracenoyl chloride (1.3 g, 5.4 mmole) in 50 ml of anhydrous CH2C12 was added dropwise to 11.6 g of hexamethylenediamine (100 mmole) in 100 ml of CH2C12 at 0°C. The solution was stirred at 0°C for 1 hour then allowed to warm to room temperature and stirred overnight. The solvent was evaporated and 200 ml of water was added to the residue. This mixture was sonicated and stirred for 1 hour then filtered. The filtered solid was dried under vacuum for 24 hours. MeOH (50 ml) and 2 ml of cone. HCl was added to the solid, followed by evaporation of MeOH. The resulting solid was washed with hot CH2Cl2/MeOH (90/10 vol. %) and recrystallized from MeOH, yielding 0.51 g of the product (26%). The purity of the product was checked by HPLC.
HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.1 mL injection, 0.75 mL/min flowrate, 2 mL injection loop, 280 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100 % B 2 min, retention time 16.5 min.
C. 9- [N- [2- (4, 4, 5,5, -tetramethyl-1, 3,2- dioxaborolano) benzyl] -N- [3-
(methacrylamido)propylamino]methyl] -10- [N- [2-(4, 4,5,5, - tetramethyl-1 , 3 ,2-dioxaborolano) benzyl] -N- [3- (N-6- (9- anthracenecarboxaxαido) hexylamino carbonylethylaminomethyl] anthracene :
9- [N- [2- (4, 4, 5, 5, -tetramethyl-1, 3, 2- dioxaborolano) benzyl] -N- [3-
(methacrylamido) propylamino] methyl] -10- [N-[2-(4, 4,5,5, - tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [2- carboxyethylamino] methyl] anthracene (40 mg, 4.5xl0"5 mole) was combined with N- ( 6-aminohexyl) -anthracene-9- carboxamide hydrochloric acid salt (20 mg, 5.6xl0"5 mole), diphenylphosphoryl azide (15.4 mg, 5.6xl0"5 mole), and 2 ml of DMF. Diisopropylethylamine (39 20 μL, 2.44xl0~4 mole) was added to the mixture and the solution was stirred at room temperature for 24 hours. The DMF was evaporated under high vacuum, the residue was dissolved
in 50 ml of EtOAc and washed with water (3x10 ml) . The EtOAc solution was separated, dried (Na2S04) , and evaporated producing 46 mg of solid (87 % yield) . Purity of the material was checked by HPLC. HPLC: HP 1100 HPLC chromatograph, Waters 5 x 100 mm NovaPak HR C18 column, 0.1 mL injection, 0.75 mL/min •flowrate, 2 mL injection loop, 280 nm detection, A = water (0.1% HFBA) and B = MeCN (0.1% HFBA), gradient 10% B 2 min, 10-80% B over 18 min, 80-100% B over 2 min, 100% B 2 min, retention time 20.42 min.
FAB mass-spectrum, glycerol matrix: calculated for C6 H75B2N5θ9 (bis glycerol adduct) [M]+=1116, found [M+l]+=1117.
II . Effect of glucose on fluorescence of indicator immobilized in hydrogel film
Preparation of HEMA/Methacrylic acid hydrogel with glucose indicator : A 50 % wt. solution of 2^hydroxyethylmethacrylate (4.75 g) and methacrylic acid (0.25 g) in phosphate buffer, pH=7.4, 200 mM was prepared. Glucose indicator (11 mg, 1.0 x 10~5 mole) and 60 mg of fructose were combined with 2 ml of MeOH. This solution was sonicated until all fructose dissolved and evaporated to yield a solid. To this solid 1 ml of phosphate buffer solution containing monomers was added. After sonication for 10 minutes this solution was filtered through 0.2 μM PTFE filter. Aqueous ammonium persulfate (20 μL, 5% wt . ) was combined with the formulation. The resulting solution was placed in a glove box purged with nitrogen. An aqueous solution of N,N,N' ,N' -tetramethylethylenediamine (40 μL, 5% wt . ) was added to the monomer formulation to accelerate polymerization. The resulting formulation was poured in
a mold constructed from microscope slides and a 100 μM stainless steel spacer. After being kept for 8 hours in a nitrogen atmosphere the mold was placed in phosphate buffered saline (10 mM, pH=7.4), the microscope slides were separated, and the hydrogel was removed. The hydrogel was washed with 100 ml of phosphate buffered saline (PBS) containing 1 mM lauryl sulfate sodium salt and 1 mM EDTA tetrasodium salt for 3 days, the solution being changed every day, followed by washing with EtOH/PBS (20/80 by vol., 3 x 100 ml), and finally with PBS (pH=7.4, 3 x 100 ml). The resulting hydrogel film was stored in PBS (10 mM, pH=7.4) containing 0.02% wt . sodium azide and 1 mM EDTA tetrasodium salt.
Effect of glucose and L-sodium lactate on hydrogel film containing glucose indicator.
The experiment was conducted in a Shimadzu RF-5301 PC spectrofluorimeter equipped with a variable temperature attachment. Excitation wavelength was set at 370 nm, slits 3/3 nm, low PMT sensitivity, emission was scanned from 400 to 600 nm. Glucose and L-sodium lactate concentrations were checked using YSI Model 2300 STAT plus glucose analyzer.
The hydrogel film (100 μm thickness, round shape - 8 mm diameter) was mounted in a PMMA cuvette at 45° angle. Phosphate buffered saline (PBS), pH=7.4 containing the desired amount of glucose, L-sodium lactate, and glucose with L-sodium lactate were heated to 37 °C in a water bath and placed in the PMMA cell containing the mounted hydrogel. After each addition the PMMA cell was allowed to equilibrate for 45 min at 37°C. Fluorescence intensity measurements for each glucose/lactate concentration were conducted on two different samples and an average value was used in the calibration curve. Calibration curves
(Fluorescence Intensity at 430 nm vs. concentration) were obtained for glucose, L-sodium lactate, and glucose in the presence of 3 mM L-sodium lactate. The results are shown in Figure 16.
EXAMPLE 14 6- (3-carboxypropionamido) hexylamino indicator monomer
Pinacol capped compound:
9- [N-[2-(4,4, 5, 5, -tetramethyl-1, 3,2- dioxaborolano) benzyl] -N- [3-
(methacrylamido) propylamino] methyl] -10-[N-[2-(4,4,5,5, tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [6- (3- carboxypropionamido) hexylamino] methyl] anthracene.
Uncapped compound:
9- [N- (2-boronobenzyl) -N- [3-
(methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl ) -N- [ 6- ( 3- carboxypropionamido) hexylamino] methyl] anthracene.
Synthesis :
The synthesis may be carried out in an analogous fashion to Example 11 using 9-[N-[3-
(methacrylamido) propylamino] methyl] -10-N- [ 6-
(hexylamino) methyl] anthracene as the starting material. In contrast, the amine starting material is reacted with the N-hydroxysuccinimide (NHS) ester of the mono methyl ester of succinic acid in place of the NHS ester of cyclohexanecarboxylic acid used in Example 11. An additional base hydrolysis step is required to complete the synthesis.
Chemical Name: N- (3-Methacrylamidopropyl) -4- [2-N- [ [2- (borono) benzyl] - [6- (N- [2- (borono) benzyl] -6-N- (3- carboxypropanamidoethyl) aminohexyl] ] aminoethylamino] napht halene-1, 8-dicarboximide
Chemical Formula: C47H6oB2N60 10
M. W. : 890
The compound may be synthesized as shown below:
EXAMPLE 16 Alternate glucose indicator/monomer excited with visible light
Chemical Name: N-Butyl-4- [2-N- [ [2- (borono) benzyl] -[ 6- (N- [2- (borono) benzyl] -6-N- (2- methacrylamidoethyl) aminohexyl] ] aminoethylamino] naphthale ne-1, 8-dicarboximide
Chemical Formula: C44H57B2N50
M. W. : 789.5 The compound may be synthesized as shown below:
Claims
1. A method for detecting the presence or concentration of glucose in a sample which may also contain an alpha-hydroxy acid or a beta-diketone, which comprises : a) exposing the sample to a compound having at least two recognition elements for glucose, oriented such that the interaction between the compound and glucose is more stable than the interaction between the compound and the alpha-hydroxy acid or beta-diketone, said compound also containing a detectable moiety having a detectable quality that changes in a concentration-dependent manner when said compound is exposed to glucose in said sample; and b) measuring any change in said detectable quality to thereby determine the presence or concentration of glucose in said sample, wherein the presence of the alpha-hydroxy acid or the beta-diketone does not substantially interfere with said determination.
2. The method of claim 1, wherein the compound has the following structure:
wherein :
-Ri and R2 are the same or different and are selected from the following : i ) hydrogen; ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-R3 is hydrogen or a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R4 and R5 are the same or different and are selected from the following: i) hydrogen, ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -each Z is independently carbon or nitrogen; -R6 and R7 are the same or different and are i) linking groups having from zero to ten contiguous or branched carbon and/or heteroatoms, or ii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R is selected from the following: i)' an aliphatic and/or aromatic spacer containing from 1 to 10 contiguous atoms selected from the group consisting of carbon, oxygen, nitrogen, sulfur and phosphorus, ii) a detectable moiety, or iii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-each R8 is the same or different and is a moiety capable of interaction with the vicinal diol groups present in glucose; and -R9 and Rio are the same or different, and are i) hydrogen, ii) a detectable moiety, iii) a group which is a) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety, and/or b) includes a functional group capable of altering the physical properties of the compound; with the proviso that the indicator compound contains at least one detectable moiety associated therewith.
3. The method of claim 2, wherein R8 is selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, and combinations thereof.
4. The method of claim 3, wherein each R8 is a boronic acid group.
5. The method of claim 2, wherein the compound comprises at least two detectable moieties that are capable of energy transport from one to the other, and wherein said energy transport is modulated by the presence of glucose in the sample.
6. The method of claim 2, wherein at least one of R, Ri, R2, R4, R5, Rg or Rio comprises a fluorophore moiety and further wherein at least one of those groups comprises a quenching moiety, and wherein said fluorophore is either quenched or dequenched when said compound interacts with glucose in the sample.
7. The method of claim 2, wherein the compound comprises a fluorophore, and the fluorescence of said fluorophore is modulated by the interaction of said compound with glucose.
8. The method of claim 1, wherein the sample is a physiological fluid.
9. The method of claim 8, wherein the physiological fluid is selected from the group consisting of blood, plasma, serum, interstitial fluid, cerebrospinal fluid, urine, saliva, intraocular fluid, lymph, tears, sweat, and physiological buffers.
10. The method of claim 1, wherein the compound is exposed to the sample in solution.
11. The method of claim 1, wherein the compound is immobilized on or within a solid support.
12. The method of claim 11, wherein the solid support is a polymeric matrix.
13. The method of claim 1, wherein the compound is associated with an implantable device, and wherein step a) takes place in vivo .
14. The method of claim 2, wherein R is an anthracene residue; Ri, R2, R3, R4 and R5 are hydrogen; R6 and R7 are dimethylamine residues; each R8 is a boronic acid group; one or both of Rg and Rio are aliphatic carboxylic acid residues; and each Z is carbon.
15. The method of claim 14, wherein one or both of R9 and Rio are propionic acid residues.
16. The method of claim 2, wherein R is a hexamethylene residue; Rl r R2, R3, R4 and R5 are hydrogen; R6 and R are dimethylamine residues; each R8 is a boronic acid group; Rg is a naphthalimide residue; RXo is a dimethylaminobenzyl residue; and each Z is carbon.
17. The method of claim 2, wherein R is an anthracene residue; Ri, R2, R3, R4 and R5 are hydrogen; R& and R7 are dimethylamine residues; each R8 is a boronic acid group; Rg and Rι0 are the same or different and are selected from the group consisting of a methacrylamidoalkyl residue, a methacroyloxyethoxyalkyl residue, a hydroxyethoxyalkyl residue, and an aminoalkyl residue; and each Z is carbon.
18. The method of claim 2, wherein the compound is selected from the group consisting of:
9- [N- (2-boronobenzyl) -N- [2- (2-methacroyloxyethoxy) - ethylamino] methyl] -10- [N- (2-boronobenzyl) -N- [2- (2-hydroxyethoxy) ethylamino]methyl] anthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [2- (carboxyethyl) amino] -methyl] anthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [3- (methacrylamido) - propylamino] methylanthracene; 9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) - propylamino]methyl] -10- [N- (2-boronobenzyl) -N- [2- (2- hydroxyethoxy) ethylamino]methyl] anthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [2- (2- methacroyloxyethoxy) ethylamino]methyl] anthracene; 9, 10-bis [N- (2-boronobenzyl) -N- [5-aminopentylamino] - methyl] anthracene; and
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino] methyl] -10- [N- (2-boronobenzyl) -N- [6- (cyclohexanecarboxamido) hexylamino] methyl] anthracene; 9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino]methyl] -10- [N- (2- boronobenzyl) -N- [2- (carboxyethyl) amino]methyl] anthracene; 9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino]methyl] -10- [N- (2- boronobenzyl) -N- [3- (N-6- (9- anthracenecarboxamido) hexylamino carbonyl) ethylamino]methyl] anthracene; 9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino]methyl] -10- [N- (2- boronobenzyl) -N- [ 6- ( 3- carboxypropionamido) hexylamino]methyl] anthracene;
N- (3-Methacrylamidopropyl) -4- [2-N- [ [2- (borono) benzyl] - [6- (N- [2- (borono) benzyl] -6-N- (3- carboxypropanamidoethyl) aminohexyl] ] aminoethylamino] napht halene-l,.8-dicarboximide;
N-Butyl-4- [2-N- [ [2- (borono) benzyl] - [6- (N- [2- (borono) benzyl] -6-N- (2- methacrylamidoethyl) aminohexyl] ] aminoethylamino] naphthale ne-1, 8-dicarboximide; and salts thereof.
19. A compound having the following structure
wherein: -R and R2 are the same or different and are selected from the following: i) hydrogen; ii) a substituent to modify the pKa and hydrolytic stability of the Rs moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R3 is hydrogen or a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-R4 and R5 are the same or different and are selected from the following: i) hydrogen, ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -each Z is independently carbon or nitrogen; -R6 and R7 are the same or different and are i) linking groups having from zero to ten contiguous or branched carbon and/or heteroatoms, or ii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R is selected from the following: i) an aliphatic and/or aromatic spacer containing from 1 to 10 contiguous atoms selected from the group consisting of carbon, oxygen, nitrogen, sulfur and phosphorus, ii) a detectable moiety, or iii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -each R8 is the same or different and is an optionally protected moiety which when unprotected is capable of interaction with the vicinal diol groups present in glucose; and -Rg and Rio are the same or different, and are i) hydrogen, ii) a detectable moiety, iii) a group which is a) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety, and/or b) includes a functional group capable of altering the physical properties of the compound; with the proviso that the indicator compound contains at least one detectable moiety associated therewith.
20. The compound of claim 19, wherein R8 is selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, all optionally protected, and combinations thereof.
21. The compound of claim 20, wherein each R8 is an optionally protected boronic acid group.
22. The compound of claim 19, wherein the compound comprises a fluorophore, and the fluorescence of said fluorophore is modulated by the interaction of said compound with glucose.
23. The compound of claim 19, wherein R is an anthracene residue; Rlf R2, R3, R4 and R5 are hydrogen; R6 and' R7 are dimethylamine residues; each R8 is an optionally protected boronic acid group; one or both of R9 and Rio are aliphatic carboxylic acid residues; and each Z is carbon.
24. The compound of claim 23, wherein one or both of Rg and Rio are propionic acid residues.
25. The compound of claim 1, wherein R is an anthracene residue; Ri, R2, R3, R4 and R5 are hydrogen; Re and R7 are dimethylamine residues; each Re is an optionally protected boronic acid group; Rg and R0 are the same or different and are selected from the group consisting of a methacrylamidoalkyl residue, a methacroyloxyethoxyalkyl residue, a hydroxyethoxyalkyl residue, and an aminoalkyl residue; and each Z is carbon.
26. The compound of claim 19, wherein the compound is selected from the group consisting of: 9- [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [2- (2-methacroyloxyethoxy) ethylamino] methyl] -10- [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [2- (2-hydroxyethoxy) ethylamino] -methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [2- (2-methacroyloxyethoxy) - ethylamino]methyl] -10- [N- (2-boronobenzyl) -N- [2- ( 2-hydroxyethoxy) ethylamino] methyl] anthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [2- (carboxyethyl) amino] -methyl] anthracene;
9, 10-bis [N- [2- (5, 5-dimethylborinan-2-yl) benzyl ] - N- [3- (methacrylamido) propylamino] methylanthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [3- (methacrylamido) - propylamino] methylanthracene;
9- [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [3- (methacrylamido) propylamino]methyl] -10- [N- [2- (5,5- dimethylborinan-2-yl) benzyl] -N- [2- (2-hydroxyethoxy) - ethylamino]methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) - propylamino] methyl] -10- [N- (2-boronobenzyl) -N- [2- (2- hydroxyethoxy) ethylamino] methyl] anthracene ; 9, 10-bis [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [2- (2-methacroyloxyethoxy) ethylamino]methyl] anthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [2- (2- methacroyloxyethoxy) ethylamino]methyl] anthracene; 9, 10-bis [N- (2-boronobenzyl) -N- [5-aminopentylamino] - methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino] methyl] -10- [N- (2-boronobenzyl) -N- [6- (cyclohexanecarboxamido) hexylamino] methyl] anthracene; 9-[N-[2- (4, 4, 5, 5, -tetramethyl-1, 3,2- dioxaborolano) benzyl]N- [3-
(methacrylamido) propylamino]methyl] -10- [N- [2- (4,4,5,5,- tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [6- (cyclohexanecarboxamido) hexylamino] methyl] anthracene; 9- [N- (2-boronobenzyl) -N- [3-
(methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl) -N- [2- (carboxyethyl) amino] methyl] anthracene;
9-[N-[2- ( , , 5, 5, -tetramethyl-1,3,2- dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino] methyl] -10-[N-[2-(4, 4,5,5, - tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [2- ( carboxyethyl) amino] methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl) -N- [3- (N-6- (9- anthracenecarboxamido) hexylamino carbonyl) ethylamino] methyl] anthracene;
9- [N- [2- (4, 4,5,5, -tetramethyl-1, 3,2- dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino] methyl] -10- [N- [2- (4,4,5,5,- tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [3- (N-6- (9- anthracenecarboxamido) hexylamino carbonylethylaminomethyl] anthracene;
9- [N- [2- ( , 4, 5, 5, -tetramethyl-1, 3,2- dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino]methyl] -10- [N- [2- (4,4,5,5,- tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [6- (3- carboxypropionamido) hexylamino] methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl) -N- [6- (3- carboxypropionamido) hexylamino] methyl] anthracene;
N- (3-Methacrylamidopropyl) -4- [2-N- [ [2- (borono) benzyl] - [6- (N- [2- (borono) benzyl] -6-N- (3- carboxypropanamidoethyl) aminohexyl] ] aminoethylamino] napht halene-1, 8-dicarboximide;
N-Butyl-4- [2-N- [ [2- (borono) benzyl] - [6- (N-[2- (borono) benzyl] -6-N- (2- methacrylamidoethyl ) aminohexyl ] ] aminoethylamino] naphthale ne-1, 8-dicarboximide; and salts thereof.
27. A detection system for detecting the presence or concentration of glucose in a sample which may also contain an alpha-hydroxy acid or a beta-diketone, which comprises a compound having the following structure
wherein: -Ri and R2 are the same or different and are selected from the following: i) hydrogen; ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R3 is hydrogen or a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety;
-R4 and R5 are the same or different and are selected from the following: i) hydrogen, ii) a substituent to modify the pKa and hydrolytic stability of the R8 moiety, iii) a detectable moiety, or iv) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -each Z is independently carbon or nitrogen; -R6 and R7 are the same or different and are i) linking groups having from zero to ten contiguous or branched carbon and/or heteroatoms, or ii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -R is selected from the following: i) an aliphatic and/or aromatic spacer containing from 1 to 10 contiguous atoms selected from the group consisting of carbon, oxygen, nitrogen, sulfur and phosphorus, ii) a detectable moiety, or iii) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety; -each R8 is the same or different and is an optionally protected moiety which when unprotected is capable of interaction with the vicinal diol groups present in glucose; and -R9 and Rio are the same or different, and are i) hydrogen, ii) a detectable moiety, iii) a group which is a) a linking group capable of attachment to a solid support or a polymeric matrix, said support or matrix optionally containing a detectable moiety, and/or b) includes a functional group capable of altering the physical properties of the compound; with the proviso that the indicator compound contains at least one detectable moiety associated therewith.
28. The detection system of claim 27, wherein R8 is selected from the group consisting of boronic acid, boronate ion, arsenious acid, arsenite ion, telluric acid, tellurate ion, germanic acid, germanate ion, all optionally protected, and combinations thereof.
29. The detection system of claim 28, wherein each R8 is an optionally protected boronic acid group.
30. The detection system of claim 27, wherein the compound comprises a fluorophore, and the fluorescence of said fluorophore is modulated by the interaction of said compound with glucose.
31. The detection system of claim 27, wherein R is an anthracene residue; Ri, R2, R3, R4 and R5 are hydrogen; Rs and R7 are dimethylamine residues; each Rs is an optionally protected boronic acid group; one or both of Rg and Rio are aliphatic carboxylic acid residues; and each Z is carbon.
32. The detection system of claim 31, wherein one or both of R9 and Ri0 are propionic acid residues.
33. The detection system of claim 27, wherein R is an anthracene residue; Ri, R2, R3, R4 and R5 are hydrogen;
Rε and R7 are dimethylamine residues; each R8 is a boronic acid group; Rg and Rio are the same or different and are selected from the group consisting of a methacrylamidoalkyl residue, a methacroyloxyethoxyalkyl residue, a hydroxyethoxyalkyl residue, and an aminoalkyl residue; and each Z is carbon.
34. The detection system of claim 27, wherein the compound is selected from the group consisting of: 9- [N-[2-(5,5-dimethylborinan-2-yl)benzyl]-N- [2- (2-methacroyloxyethoxy) ethylamino] methyl] -10- [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [2- (2-hydroxyethoxy) ethylamino] -methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [2- (2-methacroyloxyethoxy) - ethylamino]methyl] -10- [N- (2-boronobenzyl) -N- [2- (2-hydroxyethoxy) ethylamino]methyl] anthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [2- (carboxyethyl) amino] -methyl] anthracene;
9, 10-bis [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] - N- [3- (methacrylamido) propylamino] methylanthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [3- (methacrylamido) - propylamino] methylanthracene ;
9- [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [3- (methacrylamido) propylamino] methyl] -10- [N- [2- (5,5- dimethylborinan-2-yl) benzyl] -N- [2- (2-hydroxyethoxy) - ethylamino] methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) - propylamino] methyl] -10- [N- (2-boronobenzyl) -N- [2- (2- hydroxyethoxy) ethylamino] methyl] anthracene; 9, 10-bis [N- [2- (5, 5-dimethylborinan-2-yl) benzyl] -N- [2- (2-methacroyloxyethoxy) ethylamino] methyl] anthracene;
9, 10-bis [N- (2-boronobenzyl) -N- [2- (2- methacroyloxyethoxy) ethylamino]methyl] anthracene; 9, 10-bis [N- (2-boronobenzyl) -N- [5-aminopentylamino] - methyl] anthracene; and
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino] methyl] -10- [N- (2-boronobenzyl) -N- [6- (cyclohexanecarboxamido) hexylamino] methyl] anthracene; 9- [N- [2- (4, 4, 5, 5, -tetramethyl-1, 3, 2- dioxaborolano) benzyl] N- [3-
(methacrylamido) propylamino] methyl] -10- [N-[2-(4, 4,5,5, - tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [6- (cyclohexanecarboxamido) hexylamino] methyl] anthracene; 9-[N- (2-boronobenzyl) -N- [3-
(methacrylamido) propylamino] methyl] -10- [N- (2- boronobenzyl) -N- [2- (carboxyethyl) amino]methyl] anthracene;
9-[N-[2-(4,4, 5, 5, -tetramethyl-1, 3,2- dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino] methyl] -10- [N-[2-(4, 4,5,5, - tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [2- ( carboxyethyl) amino] methyl] anthracene;
9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino]methyl] -10- [N- (2- boronobenzyl) -N- [3- (N-6- (9- anthracenecarboxamido ) hexylamino carbonyl) ethylamino] methyl] anthracene;
9- [N- [2- (4 , 4, 5, 5, -tetramethyl-1, 3, 2- dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino]methyl] -10- [N- [2- (4,4,5,5,- tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [3- (N-6- (9- anthracenecarboxamido) hexylamino carbonylethylaminomethyl] anthracene ;
9-[N-[2-(4, 4, 5, 5, -tetramethyl-1, 3,2- dioxaborolano) benzyl] -N- [3- (methacrylamido) propylamino] methyl] -10-[N-[2-(4, 4,5,5, - tetramethyl-1, 3, 2-dioxaborolano) benzyl] -N- [6- (3- carboxypropionamido) hexylamino] methyl] anthracene; 9- [N- (2-boronobenzyl) -N- [3- (methacrylamido) propylamino]methyl] -10- [N- (2- boronobenzyl) -N- [6- (3- carboxypropionamido) hexylamino] methyl] anthracene;
N- (3-Methacrylamidopropyl) -4- [2-N- [ [2- (borono) benzyl] - [6- (N- [2- (borono) benzyl] -6-N- (3- carboxypropanamidoethyl ) aminohexyl] ] aminoethylamino] napht halene-1, 8-dicarboximide;
N-Butyl-4- [2-N- [ [2- (borono) benzyl] -[ 6- (N-[2- (borono) benzyl] -6-N- (2- methacrylamidoethyl) aminohexyl] ] aminoethylamino] naphthale ne-1, 8-dicarboximide; and salts thereof.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003220293A AU2003220293B2 (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydyroxy acid or a beta-diketone |
| AT03716591T ATE468335T1 (en) | 2002-03-14 | 2003-03-14 | DETECTION OF GLUCOSE IN SOLUTIONS THAT ALSO CONTAIN ALPHA-HYDROXY ACID OR A BETA-DIKETONE |
| DK03716591.7T DK1490359T3 (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| SI200331850T SI1490359T1 (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| MXPA04008931A MXPA04008931A (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone. |
| KR1020047014463A KR101012325B1 (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| CA2478979A CA2478979C (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| JP2003576429A JP4431398B2 (en) | 2002-03-14 | 2003-03-14 | Glucose detection in solutions containing α-hydroxy acids or β-diketones |
| DE60332609T DE60332609D1 (en) | 2002-03-14 | 2003-03-14 | DETERMINATION OF GLUCOSE IN SOLUTIONS ALSO CONTAINING ALPHA HYDROXYLIC ACID OR BETA DIETETONE |
| BR0308412-4A BR0308412A (en) | 2002-03-14 | 2003-03-14 | Glucose detection in solutions also containing an alpha hydroxy acid or a beta diketone |
| EP03716591A EP1490359B1 (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| HK05103674.2A HK1071130A1 (en) | 2002-03-14 | 2005-04-29 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36388502P | 2002-03-14 | 2002-03-14 | |
| US60/363,885 | 2002-03-14 | ||
| US10/187,903 US6800451B2 (en) | 2001-01-05 | 2002-07-03 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
| US10/187,903 | 2002-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003078424A1 true WO2003078424A1 (en) | 2003-09-25 |
Family
ID=28044431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2003/007938 WO2003078424A1 (en) | 2002-03-14 | 2003-03-14 | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6800451B2 (en) |
| EP (1) | EP1490359B1 (en) |
| JP (1) | JP4431398B2 (en) |
| KR (1) | KR101012325B1 (en) |
| AU (1) | AU2003220293B2 (en) |
| BR (1) | BR0308412A (en) |
| CA (1) | CA2478979C (en) |
| MX (1) | MXPA04008931A (en) |
| WO (1) | WO2003078424A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006036664A (en) * | 2004-07-23 | 2006-02-09 | Terumo Corp | Saccharide-measuring fluorescent monomer compound, saccharide-measuring fluorescent sensor substance and implantatble saccharide-measuring sensor |
| JP2006104140A (en) * | 2004-10-07 | 2006-04-20 | Terumo Corp | Fluorescent monomer compound for measuring saccharides, fluorescent sensor substance for measuring saccharides, and saccharides-measuring sensor to be embedded in the body |
| WO2008066921A2 (en) | 2006-11-30 | 2008-06-05 | Sensors For Medicine And Science, Inc. | Oxidation resistant indicator molecules |
| EP3562952A4 (en) * | 2016-12-27 | 2020-08-05 | Profusa, Inc. | Near-ir glucose sensors |
| US11866588B2 (en) | 2016-12-21 | 2024-01-09 | Profusa, Inc. | Polymerizable near-IR dyes |
| US12048535B2 (en) | 2013-03-14 | 2024-07-30 | Profusa, Inc | Oxygen sensors |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211507A1 (en) * | 1996-03-29 | 2003-11-13 | Anson Hatch | Microscale diffusion immunoassay in hydrogels |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6664407B2 (en) * | 2000-12-04 | 2003-12-16 | Beckman Coulter, Inc. | Electrochemical saccharide sensor |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US7041468B2 (en) | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| AU2003287735A1 (en) * | 2002-11-12 | 2004-06-03 | Argose, Inc. | Non-invasive measurement of analytes |
| US20040106163A1 (en) * | 2002-11-12 | 2004-06-03 | Workman Jerome James | Non-invasive measurement of analytes |
| US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
| US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
| US8029765B2 (en) | 2003-12-24 | 2011-10-04 | Masimo Laboratories, Inc. | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors |
| CA2556331A1 (en) | 2004-02-17 | 2005-09-29 | Therasense, Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| US7713745B2 (en) * | 2004-04-13 | 2010-05-11 | Sensors For Medicine And Science, Inc. | Non-covalent immobilization of indicator molecules |
| DE602005000858T2 (en) * | 2004-07-23 | 2008-01-17 | Terumo K.K. | Saccharide-measuring fluorescent monomer, saccharide-measuring fluorescent sensor substance and implantable saccharide-measuring sensor |
| US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
| US7766829B2 (en) | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
| US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
| US7809441B2 (en) | 2006-05-17 | 2010-10-05 | Cardiac Pacemakers, Inc. | Implantable medical device with chemical sensor and related methods |
| US20080064937A1 (en) | 2006-06-07 | 2008-03-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
| ATE514755T1 (en) * | 2006-07-25 | 2011-07-15 | Glumetrics Inc | FLUORESCENT DYES FOR USE IN GLUCOSE DETECTION |
| EP2120680A2 (en) | 2007-02-06 | 2009-11-25 | Glumetrics, Inc. | Optical systems and methods for rationmetric measurement of blood glucose concentration |
| US7751863B2 (en) * | 2007-02-06 | 2010-07-06 | Glumetrics, Inc. | Optical determination of ph and glucose |
| US7829341B2 (en) | 2007-07-11 | 2010-11-09 | Glumetrics, Inc. | Polyviologen boronic acid quenchers for use in analyte sensors |
| US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
| US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
| US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
| US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| EP2150814A2 (en) * | 2007-05-10 | 2010-02-10 | Glumetrics, Inc. | Device and methods for calibrating analyte sensors |
| JP5517919B2 (en) * | 2007-05-10 | 2014-06-11 | グルメトリクス、 インク． | Balanced non-consumable fluorescent sensor for immediate intravascular glucose measurement |
| WO2008153930A1 (en) * | 2007-06-08 | 2008-12-18 | The Charles Stark Draper Laboratory, Inc. | Sensors for the detection of diols and carbohydrates using boronic acid chelators for glucose |
| US20090014340A1 (en) * | 2007-06-15 | 2009-01-15 | Williams John R | Devices, systems, and methods for measuring glucose |
| EP2181160B1 (en) | 2007-08-06 | 2016-05-11 | Medtronic Minimed, Inc. | Hpts-mono cys-ma polymerizable fluorescent dyes for use in analyte sensors |
| US20090247984A1 (en) * | 2007-10-24 | 2009-10-01 | Masimo Laboratories, Inc. | Use of microneedles for small molecule metabolite reporter delivery |
| WO2009067626A1 (en) | 2007-11-21 | 2009-05-28 | Glumetrics, Inc. | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
| WO2009129186A2 (en) | 2008-04-17 | 2009-10-22 | Glumetrics, Inc. | Sensor for percutaneous intravascular deployment without an indwelling cannula |
| US8181531B2 (en) * | 2008-06-27 | 2012-05-22 | Edwin Carlen | Accessible stress-based electrostatic monitoring of chemical reactions and binding |
| US9011670B2 (en) * | 2008-08-14 | 2015-04-21 | The Charles Stark Draper Laboratory, Inc. | Three-dimensional metal ion sensor arrays on printed circuit boards |
| US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
| US9226701B2 (en) | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
| US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
| EP2473099A4 (en) | 2009-08-31 | 2015-01-14 | Abbott Diabetes Care Inc | Analyte monitoring system and methods for managing power and noise |
| US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
| US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
| JP2013506503A (en) | 2009-09-30 | 2013-02-28 | グルメトリクス， インコーポレイテッド | Sensor with antithrombogenic coating |
| US8467843B2 (en) | 2009-11-04 | 2013-06-18 | Glumetrics, Inc. | Optical sensor configuration for ratiometric correction of blood glucose measurement |
| EP2534470B1 (en) | 2010-02-08 | 2016-08-10 | Medtronic Minimed, Inc. | Antioxidant protection of a chemical sensor |
| WO2011113020A1 (en) * | 2010-03-11 | 2011-09-15 | Glumetrics, Inc. | Measurement devices and methods for measuring analyte concentration incorporating temperature and ph correction |
| WO2012043177A1 (en) * | 2010-09-30 | 2012-04-05 | テルモ株式会社 | Florescent hydrogel, method for manufacturing same, and sensor for measuring saccharides using same |
| JP6084172B2 (en) | 2011-03-15 | 2017-02-22 | センセオニクス，インコーポレーテッド | Integrated catalytic protection of oxidation sensitive materials |
| WO2013012687A2 (en) | 2011-07-15 | 2013-01-24 | Glumetrics, Inc. | Combinations of fluorphores and pyridinium boronic acid quenchers for use in analyte sensors |
| US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
| WO2014003075A1 (en) | 2012-06-26 | 2014-01-03 | 京セラ株式会社 | Sensor, detection method, detection system, and detection device |
| US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
| KR101517963B1 (en) | 2012-11-09 | 2015-05-06 | 한국세라믹기술원 | Water sensitive phosphor, manufacturing method thereof and water and defection detecting sensor comprising said water sensitive phosphor |
| US9181389B2 (en) * | 2013-05-20 | 2015-11-10 | Xerox Corporation | Alizarin-based polymer colorants |
| KR101440547B1 (en) | 2013-05-20 | 2014-09-17 | 한국화학연구원 | Anthracene derivatives for metal ions, preparation method thereof and selective detection method of metal ions using the same |
| US9963556B2 (en) | 2013-09-18 | 2018-05-08 | Senseonics, Incorporated | Critical point drying of hydrogels in analyte sensors |
| US9814413B2 (en) | 2014-07-24 | 2017-11-14 | Thomas Jefferson University | Long-term implantable monitoring system and methods of use |
| US10716500B2 (en) | 2015-06-29 | 2020-07-21 | Cardiac Pacemakers, Inc. | Systems and methods for normalization of chemical sensor data based on fluid state changes |
| WO2018184012A1 (en) | 2017-03-31 | 2018-10-04 | Capillary Biomedical, Inc. | Helical insertion infusion device |
| CN108968976B (en) | 2017-05-31 | 2022-09-13 | 心脏起搏器股份公司 | Implantable medical device with chemical sensor |
| WO2019023093A1 (en) | 2017-07-26 | 2019-01-31 | Cardiac Pacemakers, Inc. | Systems and methods for disambiguation of posture |
| CN109381195B (en) | 2017-08-10 | 2023-01-10 | 心脏起搏器股份公司 | Systems and methods including electrolyte sensor fusion |
| CN109419515B (en) | 2017-08-23 | 2023-03-24 | 心脏起搏器股份公司 | Implantable chemical sensor with staged activation |
| CN109864746B (en) | 2017-12-01 | 2023-09-29 | 心脏起搏器股份公司 | Multimode analyte sensor for medical devices |
| CN109864747B (en) | 2017-12-05 | 2023-08-25 | 心脏起搏器股份公司 | Multimode analyte sensor optoelectronic interface |
| AU2019293250A1 (en) * | 2018-06-27 | 2021-01-07 | Profusa, Inc. | Near-IR glucose sensors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5503770A (en) * | 1993-11-07 | 1996-04-02 | Research Development Corporation Of Japan | Fluorescent compound suitable for use in the detection of saccharides |
| US6344360B1 (en) * | 1998-03-11 | 2002-02-05 | Sensors For Medicine And Science, Inc. | Detection of analytes by fluorescent lanthanide metal chelate complexes containing substituted ligands |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516645A (en) * | 1994-04-25 | 1996-05-14 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay analytical elements containing vanadium IV(V+4)ions |
| US5998594A (en) * | 1994-12-30 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Self-assembling, chromogenic receptors for the recognition of medically important substrates and their method of use |
| JP2799837B2 (en) | 1995-03-03 | 1998-09-21 | 科学技術振興事業団 | Boronic acid compounds having a binaphthyl group |
| US6063637A (en) * | 1995-12-13 | 2000-05-16 | California Institute Of Technology | Sensors for sugars and other metal binding analytes |
| US6511814B1 (en) * | 1999-03-26 | 2003-01-28 | Idexx Laboratories, Inc. | Method and device for detecting analytes in fluids |
| US6366793B1 (en) * | 1999-09-10 | 2002-04-02 | Beckman Coulter, Inc. | Minimally invasive methods for measuring analtes in vivo |
| EP1557422B1 (en) * | 2000-08-04 | 2013-12-25 | Senseonics, Incorporated | Detection of analytes in aqueous environments |
| US20020127626A1 (en) * | 2001-01-05 | 2002-09-12 | Sensors For Medicine And Science, Inc. | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
-
2002
- 2002-07-03 US US10/187,903 patent/US6800451B2/en not_active Expired - Fee Related
-
2003
- 2003-03-14 CA CA2478979A patent/CA2478979C/en not_active Expired - Fee Related
- 2003-03-14 MX MXPA04008931A patent/MXPA04008931A/en active IP Right Grant
- 2003-03-14 BR BR0308412-4A patent/BR0308412A/en not_active Application Discontinuation
- 2003-03-14 KR KR1020047014463A patent/KR101012325B1/en not_active IP Right Cessation
- 2003-03-14 EP EP03716591A patent/EP1490359B1/en not_active Expired - Lifetime
- 2003-03-14 JP JP2003576429A patent/JP4431398B2/en not_active Expired - Fee Related
- 2003-03-14 WO PCT/US2003/007938 patent/WO2003078424A1/en active Application Filing
- 2003-03-14 AU AU2003220293A patent/AU2003220293B2/en not_active Ceased
-
2004
- 2004-10-04 US US10/956,133 patent/US7078554B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5503770A (en) * | 1993-11-07 | 1996-04-02 | Research Development Corporation Of Japan | Fluorescent compound suitable for use in the detection of saccharides |
| US6344360B1 (en) * | 1998-03-11 | 2002-02-05 | Sensors For Medicine And Science, Inc. | Detection of analytes by fluorescent lanthanide metal chelate complexes containing substituted ligands |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1490359A4 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006036664A (en) * | 2004-07-23 | 2006-02-09 | Terumo Corp | Saccharide-measuring fluorescent monomer compound, saccharide-measuring fluorescent sensor substance and implantatble saccharide-measuring sensor |
| JP4691333B2 (en) * | 2004-07-23 | 2011-06-01 | テルモ株式会社 | Fluorescent monomer compound for saccharide measurement, fluorescent sensor substance for saccharide measurement, and saccharide measurement sensor for implantation in the body |
| JP2006104140A (en) * | 2004-10-07 | 2006-04-20 | Terumo Corp | Fluorescent monomer compound for measuring saccharides, fluorescent sensor substance for measuring saccharides, and saccharides-measuring sensor to be embedded in the body |
| JP4691345B2 (en) * | 2004-10-07 | 2011-06-01 | テルモ株式会社 | Fluorescent monomer compound for saccharide measurement, fluorescent sensor substance for saccharide measurement, and saccharide measurement sensor for implantation in the body |
| WO2008066921A2 (en) | 2006-11-30 | 2008-06-05 | Sensors For Medicine And Science, Inc. | Oxidation resistant indicator molecules |
| WO2008066921A3 (en) * | 2006-11-30 | 2008-07-17 | Sensors For Med & Science Inc | Oxidation resistant indicator molecules |
| US7851225B2 (en) | 2006-11-30 | 2010-12-14 | Sensors For Medicine And Science, Inc. | Oxidation resistant indicator molecules |
| US8143068B2 (en) | 2006-11-30 | 2012-03-27 | Sensors For Medicine And Science, Inc. | Oxidation resistant indicator molecules |
| KR101492849B1 (en) | 2006-11-30 | 2015-02-12 | 센세오닉스, 인코포레이티드 | Oxidation resistant indicator molecules |
| US12048535B2 (en) | 2013-03-14 | 2024-07-30 | Profusa, Inc | Oxygen sensors |
| US11866588B2 (en) | 2016-12-21 | 2024-01-09 | Profusa, Inc. | Polymerizable near-IR dyes |
| EP3562952A4 (en) * | 2016-12-27 | 2020-08-05 | Profusa, Inc. | Near-ir glucose sensors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101012325B1 (en) | 2011-02-08 |
| MXPA04008931A (en) | 2004-12-13 |
| BR0308412A (en) | 2005-03-29 |
| AU2003220293B2 (en) | 2009-10-15 |
| JP4431398B2 (en) | 2010-03-10 |
| US7078554B2 (en) | 2006-07-18 |
| JP2005530130A (en) | 2005-10-06 |
| KR20040091138A (en) | 2004-10-27 |
| CA2478979A1 (en) | 2003-09-25 |
| EP1490359A1 (en) | 2004-12-29 |
| EP1490359A4 (en) | 2006-08-23 |
| US20030082663A1 (en) | 2003-05-01 |
| EP1490359B1 (en) | 2010-05-19 |
| US20050043275A1 (en) | 2005-02-24 |
| US6800451B2 (en) | 2004-10-05 |
| AU2003220293A1 (en) | 2003-09-29 |
| CA2478979C (en) | 2011-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6800451B2 (en) | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone | |
| US20020127626A1 (en) | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone | |
| US7939332B2 (en) | Detection of analytes in aqueous environments | |
| US20020119581A1 (en) | Detection of analytes | |
| AU2001278145A1 (en) | Detection of analytes in aqueous environments | |
| US20020090734A1 (en) | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone | |
| US20020094586A1 (en) | Detection of analytes | |
| ES2345194T3 (en) | GLUCOSE DETECTION THAT ALSO CONTAINS A HYDROXIACID ALPHA OR A DICETONE BETA. | |
| AU2002245213A1 (en) | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone | |
| AU2002246941A1 (en) | Detection of analytes | |
| TW200401034A (en) | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2478979 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003576429 Country of ref document: JP Ref document number: 1020047014463 Country of ref document: KR Ref document number: PA/a/2004/008931 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003220293 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 01474/KOLNP/2004 Country of ref document: IN Ref document number: 1474/KOLNP/2004 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003716591 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020047014463 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 20038107562 Country of ref document: CN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003716591 Country of ref document: EP |